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ABSTRACT 
Spontaneous abortion (SAB) is the unexpected loss of a conceptus early in 
pregnancy. Methodologic limitations such as left truncation bias, recall bias, and 
misclassification have prevented investigators from identifying risk factors related to this 
adverse pregnancy outcome. The objective of this dissertation was to examine the 
associations of body size, caffeine consumption, and history of oral contraceptive (OC) 
use with SAB risk among a prospective cohort of pregnancy planners in Denmark. 
In study 1, we examined SAB risk in relation to body size as measured by body 
mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), height, and 
location of typical weight gain. We found that overall obesity (defined as BMI230) was 
associated with an increased risk of SAB, especially for pregnancy losses before 8 
gestational weeks. Increasing WHR and increasing height were associated with a 
decreased risk ofSAB. Underweight, WC, and location ofweight gain were not 
materially associated with SAB risk. 
The second study evaluated risk of SAB in relation to consumption of caffeine 
and caffeinated beverages before conception and during early pregnancy. We found that 
women who consumed higher amounts of coffee per day before pregnancy had a slightly 
Vl 
higher risk of SAB. Overall, increased caffeine consumption during early pregnancy was 
also associated with higher risk of SAB. 
Study 3 assessed the risk of SAB in relation to self-reported history of OC use, 
evaluated in terms of recency, duration, and formulation of the most recent pill. Recent 
and longer durations of OC use were independently associated with a decreased risk of 
SAB. When stratified by maternal age, younger women ( <30 years) had an increased risk 
of SAB with longer duration but older women (~30 years) had a decreased risk of SAB. 
Vll 
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1 INTRODUCTION 
Spontaneous abortion (SAB) is the unexpected loss of a fetus early in pregnancy. 
Estimates of the prevalence of SAB depend strongly on the method used to identify early 
pregnancy and capture embryonic or fetal death. Misclassification of SAB status can 
lead to biased measures of association.1 A population-based cohort study in Denmark 
estimated a 20.9% risk of SAB among 20-29 year-olds using registry linkage and self-
report,2 and a rigorous study of early pregnancy loss using daily urinary human chorionic 
gonadotropin (hCG) measurements estimated that 25% of all clinically-recognized 
pregnancies end in SAB.3•4 
The etiology of SAB is notoriously difficult to study because current methods of 
pregnancy detection require intensive surveillance and can only detect a conceptus that 
has already implanted in the uterus.5 Thus, a non-negligible proportion of SABs, those 
occurring immediately after implantation, are missed in traditional epidemiologic studies. 
Advanced maternal age, chromosomal abnormalities, smoking, and previous SAB remain 
the most consistently identified risk factors for SAB.3•6•7 Previous investigations have also 
implicated endocrine and anatomic abnormalities, abnormal blood coagulation, 
environmental contaminants, and lifestyle factors such as alcohol consumption as risk 
factors for SAB,6 but results have been inconclusive. Despite the fact that SAB has been 
a frequent topic of investigation, there exist no reliable clinical recommendations for 
women planning a pregnancy on how to avoid this adverse pregnancy outcome. 
Using prospective data from a Danish cohort study of pregnancy planners aged 18-40 
years, this doctoral dissertation examines the risk of SAB in relation to body size, 
1 
caffeine consumption, and oral contraceptive use. 
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2 BODY SIZE AND SPONTANEOUS ABORTION 
2.1 INTRODUCTION 
The prevalence of obesity is increasing worldwide. 1'2 In Denmark, the prevalence 
of obesity has exhibited a marked increase within the past 25 to 30 years,3 particularly for 
reproductive-aged women, of whom 9.7% were obese in 2006-2007.4 Studies have 
reported that both obesity5-8 and underweight9' 10 are associated with ·increased risk of 
spontaneous abortion (SAB). 
Obesity is associated with disturbances in sex hormone metabolism, 11 ' 12 
reproductive disorders, 13 intrauterine and urinary tract infections/4- 17 and disruptions in 
the follicular environment including increased inflammation. 18 Although few studies have 
examined risk of SAB among underweight women, lower maternal serum leptin levels 
and poor nutritional status have been hypothesized to increase SAB risk in this group.9' 10 
Using data from a prospective cohort of pregnancy planners in Denmark, we 
examined risk of SAB in relation to selected anthropometric factors , including body mass 
index (BMI), perceived weight gain distribution, height, waist circumference (WC), and 
waist-to-hip ratio (WHR). 
2.2 METHODS 
2.2. 1 Data collection 
The Snart~Gravid study is an Internet-based prospective cohort study of time to 
pregnancy. Recruitment began in 2007 when an advertisement was placed on a Danish 
health-related website (www.netdoktor.dk) and a coordinated media strategy was 
launched. 19-21 Enrollment and primary data collection were conducted via a self-
4 
administered questionnaire on the study website (www.snart-gravid.dk). Contact with 
participants was maintained through the website and e-mail. 
Before enrollment, participants completed a consent form and an online screening 
questionnaire to verify eligibility. Women eligible to participate in Snart Gravid were 
aged 18-40 years, residents of Denmark, in a stable relationship with a male partner, not 
using fertility treatment, and trying to become pregnant. Participants were required to 
provide a valid e-mail address and their Civil Personal Registration (CPR) number, a 
unique 1 0-digit personal identification number assigned to each Danish resident. After 
38 months of recruitment, 5,921 women had enrolled in the study. The study was 
approved by the Danish Data Protection Board and the Institutional Review Board of 
Boston University Medical Campus. 
The baseline questionnaire collected information on demographics, lifestyle and 
behavioral factors, and reproductive and medical history. Initially, women were 
randomized with equal probability to receive either a short- or long-form version of the 
baseline questionnaire. Because completion rates and missing data were similar for both 
questionnaires, 21 after six months all new participants received the long-form baseline 
questionnaire. Participants were contacted every two months by e-mail with a reminder 
to fill out a follow-up questionnaire. Follow-up questionnaires assessed changes in 
exposures and pregnancy status, including whether any clinically-recognized pregnancy 
losses had occurred. Follow-up continued until conception occurred or for a maximum of 
12 months. 
To obtain information on pregnancy outcomes among women in the cohort, we 
5 
linked each woman's CPR number to the Danish National Registry of Patients (DNRP) 
and Danish Medical Birth Registry (DMBR) records through 2012. The DNRP provides 
information on hospital, emergency room, specialist, and outpatient encounters (including 
SAB and therapeutic abortion (TAB)). The DMBR gives information on all live and still 
births after 22 gestational weeks.22'23 Pregnancy outcomes occurring after the baseline 
enrollment date in the Snart Gravid cohort were identified using ICD-10 codes (D003 for 
SAB and D004 for TAB) in the DNRP. A validation study ofDNRP data found that 
30% of self-reported SABs were not registered in the DNRP;24 however, this study 
examined records from 1991-1995, before the registry started to include data from 
outpatient clinics (2:1995). Another study that compared the DNRP with data from 
individual medical records found a positive predictive value of 98 . 7%.23 
2.2.2 Assessment of anthropometric measures 
Participants' height (em) and weight (kg) before conception were reported on the 
baseline questionnaire. Women were also asked 'When you gain weight, where on your 
body do you mainly add the weight?' Possible responses were 'equally all over', 
'waist/stomach' , 'hips/thighs', 'chest/shoulders', and 'do not gain weight'. On the long-
form questionnaire (asked of 50% of participants in the first 6 months of the study and all 
participants thereafter), women reported their WC (em) at the level of the umbilicus and 
their hip circumference (em) at its widest location. Respondents were asked if they had 
used a measuring tape to make these measurements (yes/no). We used BMI (kg/m2) to 
measure total adiposity, WHR to measure the relative distribution of body fat, and WC to 
estimate abdominal visceral adiposity.25-27 Because taller women tend to have larger 
6 
waist circumferences, we created a measure of height-adjusted we by regressing we on 
height and adding an amount equal to the predicted change in waist size corresponding to 
a participant's departure from the average height in our cohort.25 
2.2.3 Assessment of spontaneous abortion 
The outcome of interest was SAB. We used two sources of data to ascertain 
SABs: data from the DNRP and self-reported data from follow-up questionnaires. On the 
follow-up questionnaire, women who reported a pregnancy loss were asked to report the 
date of the loss and how long the pregnancy lasted (in weeks since the last menstrual 
period). The DNRP provided information on occurrences of SAB up to 22 gestational 
weeks and any TAB, the dates of these events, and the gestational age at which the 
pregnancy ended, as measured by ultrasound fetometry. For pregnancy losses recorded 
in both the registry and on a questionnaire, we used data from the DNRP (based on either 
early ultrasound fetometry or LMP) to measure gestational week of pregnancy loss. In 
Denmark, the first pregnancy-related ultrasound is around 12 weeks of gestation so 
gestational ages of SABs after this time are likely based on ultrasound. For SABs 
reported only on a Snart Gravid follow-up questionnaire, gestational age was calculated 
the number of weeks from the last menstrual period to the date of pregnancy loss, 
rounded to the nearest whole week. Among the women who had a SAB reported in both 
sources, the correlation between gestational weeks reported on an SG questionnaire and 
in the registry was 0.71. The mean reported gestational age from SG was slightly lower 
7.2 vs. 7.3 weeks in the registry. 
There were 163 women who reported a pregnancy on a Snart Gravid follow-up 
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questionnaire but did not have any data from that pregnancy recorded in either the 
hospital or birth registries. For this analysis, we assumed that these women had an early 
SAB. We used multiple imputation to impute a gestational age ~12 weeks for each of 
these presumed SABs. Sensitivity analyses in which we excluded these pregnancies 
produced results similar to those in our primary analysis (See Appendix Table 1 ). 
2. 2. 4 Assessment of confounders 
Data on maternal age, parity, smoking status, alcohol and caffeine consumption, 
physical activity, and vocational training/education were reported on the baseline 
questionnaire. We estimated total metabolic equivalents (METs) per week by summing 
the METs from moderate physical activity (hours per week multiplied by 3.5 METs) and 
vigorous exercise (hours per week multiplied by 7.0 METs).28 Smoking status and 
consumption of alcohol and caffeine were updated on all subsequent follow-up 
questionnaires. 
2. 2. 5 Study population 
The present analysis was restricted to the first clinically-recognized pregnancy 
experienced by women after enrollment in the cohort. Only the first pregnancy after 
enrollment was included because anthropometric variables are known to change after 
childbirth29 and exposure information for subsequent pregnancies could have been 
misclassified. In addition, we excluded 126 women because they were not living in 
Denmark during follow-up, 10 women who did not provide a valid CPR, and 653 (11 %) 
women who did not conceive during the follow-up period (as indicated by the absence of 
8 
pregnancy data on the follow-up questionnaires, the DNRP, and the DMBR) (See Figure 
2.1). 
2.2. 6 Data analysis 
We assessed the relationship between pre-pregnancy anthropometric factors and 
SAB using a time-to-event analysis. Time to SAB was measured in gestational weeks. 
We divided female BMI (kg/m2) into the following categories: <20, 20-24, 25-29, and 
2:30. With the exception ofthe lowest category, the categories ofBMI were based on 
WHO guidelines. The categories ofWC and WHR were <75 em, 75-79 em, 80-86 em, 
2:87 em and <0.75, 0.75-0.79, 0.80-0.84, 2:0.85, respectively. These categories were 
determined based on other clinical literature that has suggested higher risks of morbidity 
and mortality with higher WC and WHR.30•31 Height was categorized into quartiles of 
<166 em, 166-169 em, 170-173 em, and 2:174 em. The typical location of weight gain 
was analyzed in the original categories described above. We examined the shape and 
magnitude of the relation between each continuous anthropometric variable and SAB risk 
by using restricted cubic splines. 32 
We used Cox proportional hazards regression models, with gestational weeks as 
the time scale, to estimate hazard ratios (HRs) and 95% confidence intervals (Cis) for 
anthropometric variables associated with SAB. We assumed that there was a true but 
unknown ordering for tied event times and used the "exact" option in SAS PROC 
PHREG,33 which takes into account all possible orderings of event times. The HR may 
be interpreted as the average per-week risk of SAB for the exposed category divided by 
the corresponding risk for the reference category. TABs were censored at the week of 
9 
pregnancy termination and pregnancies lasting more than 22 weeks were censored at 22 
weeks. 
We selected potential confounders from a group of variables associated with SAB 
and the anthropometric variables at baseline, and those meeting qualitative criteria for 
confounding based on a review of the literature and the assessment of causal graphs.34 
The variables included were maternal age, cigarette smoking, parity, vocational 
training/education, physical activity, alcohol and caffeine consumption. We controlled 
for potential confounders that changed the crude HR by more than 5% in univariate 
analyses. Both crude and adjusted models are presented in Table 2, although there was 
little confounding. We first controlled for both the baseline and most recent values of 
. caffeine, alcohol, and smoking. Because they yielded similar estimates, we used baseline 
values. Additional models are presented simultaneously controlling for other measures of 
adiposity (BMI models adjusted for WC, height models adjusted for weight, and all other 
models adjusted for BMI). 
In secondary analyses, we assessed whether the HRs were similar for women who 
differed by waiting time to pregnancy for the index pregnancy ( <6 vs. 2:6 months), parity 
(nulliparous vs. parous), maternal age (<30 years vs. 2:30 years), and menstrual cycle 
regularity (yes vs. no), defined in the questionnaire as a woman's ability to predict when 
her next menstrual period will start. Because the etiology of pregnancy loss likely differs 
for early and late losses/5•36 especially by karyotype, we also examined the association 
between each exposure and time timing of pregnancy losses ( <8 vs. 2:8 weeks of 
gestation). The choice of 8 weeks as a cut point for evaluating the timing of pregnancy 
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loss was based on karyotype data showing a higher proportion of chromosomal 
abnormalities prior to 8 weeks.37 
We used multiple imputation methods to impute missing covariate, exposure, and 
outcome information. 38 Missing data ranged from 0% for maternal age, time to 
pregnancy, and smoking status to 6% for number of glasses of dessert wine consumed per 
week. As a result of randomization to long and short questionnaires during the first six 
months of enrollment, 30% of waist and hip measurements were missing from the 
baseline questionnaire. An additional33% ofwaist and hip circumferences were missing 
due to nonresponse. We used PROC MI to create 5 imputed datasets based on 33 
variables in the imputation model. We combined beta coefficients and standard errors 
across the imputed datasets using PROC MIANAL YZE. 
To assess departures from the proportional hazards assumption we plotted log-log 
survivor functions for each variable in categorical form. In the log-log survivor 
functions, parallel curves indicated proportional hazards. SAS statistical software 
(version 9.3, SAS Institute) was used for all analyses. 
2.3 RESULTS 
Among the 5,132 women who reported a pregnancy or for whom there was 
registry-based evidence of a pregnancy after enrolling in the Snart Gravid study, a total of 
732 participants (14.3%) had a SAB. Overall, 26% of SABs were recorded only in the 
DNRP, 36% were reported only on a Snart Gravid follow-up questionnaire, 16% were 
documented in both sources, and 22% were women who reported a pregnancy on a 
follow-up questionnaire but had no outcome information in the registries (See Table 2.1 ). 
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Half of women who reported waist and hip circumferences used a tape measure. 
Baseline characteristics of study participants according to BMI and WHR are presented 
in Table 2.2. BMI was positively associated with parity, lower levels of vocational 
training, lower caffeine and alcohol consumption, and sedentary activity. WHR was also 
positively associated with smoking more cigarettes per day. The number of SABs by 
maternal age and BMI categories is presented in Table 2.3. In general, the risk of SAB 
increased with increasing maternal age, although results were not entirely consistent 
across categories of BMI. Pearson correlation coefficients were 0.31 for BMI vs. WHR, 
0.84 for BMI vs. We, and 0.64 for WHR vs. we. 
After adjustment for all covariates except we, the HRs for SAB among 
underweight, overweight, and obese women were 1.00 [95% ei: 0.81 , 1.24], 0.90 [95% 
ei: 0.73, 1.09] and 1.23 [95% ei: 0.98, 1.54], respectively, compared with normal weight 
women. After controlling for we, the HRs remained similar (Table 2.4). Results were 
also similar when a cut-point of 18.5 kg/m2 instead of 20 kg/m2 for underweight was 
used. Figure 2.2 displays the association between BMI and the risk of SAB by gestational 
week using restricted cubic splines. The curve indicates little association with increasing 
BMI until a BMI of30, and then a steep rise in the HR as BMI increases from 30 to 40. 
The shape of the spline curve is consistent with the fmdings from our categorical 
analyses. 
we was not materially associated with SAB risk in the fully adjusted model. 
With the addition ofBMI to the model, increasing we was associated with a slightly 
decreased risk of SAB. HRs for we 75-79 em, 80-86 em, and 2:87 em were 0.91 [95% 
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ei: 0.71, 1.17], 0.80 [95% ei: 0.61, 1.06], and 0.88 [95% ei: 0.57, 1.36], respectively, 
relative to women with a we < 75 em. Increasing WHR also was associated with a small 
decrease in SAB risk. HRs for WHR 0.75-0.79, 0.80-0.84 and ~0 . 85 were 0.85 [95% ei: 
0.67, 1.06], 0.76 [95% ei: 0.58, 1.00], and 0.81 [95% ei: 0.63, 1.05], respectively, 
relative to WHR < 0.75. Further adjustment for BMI did not change the observed HRs 
noticeably (Table 2.4). HRs derived from a complete case analysis ofWe and WHR 
were similar to the original results based on multiple imputation as were results among 
women who used a tape measure to provide waist and hip circumferences (Table 2.5). 
Women who were 17 4 em or taller had a 19% decreased risk of SAB relative to 
women who were <166 em (HR: 0.81; [95% ei: 0.66, 1.00]). Heights between 166-169 
em and 170-173 em showed little association with SAB risk (Table 2.4). Further 
adjustment for weight did not produce substantially different HRs. 
No appreciable differences in SAB risk were found among women who tended to 
gain weight in their waist/stomach and hips/thighs compared with women who tended to 
gain weight equally all over (Table 2.4). HRs were 0.88 for women who reported that 
they tended not to gain weight [95% ei: 0.59, 1.32] and 1. 15 for women who gained 
weight in their chest/shoulders [95% ei: 0.50, 2.65], respectively, though there were few 
SABs in each of these groups (27 and 9, respectively). Adjustment for BMI had little 
effect on the observed results. 
The risk of SAB earlier than 8 weeks of gestation was 1.34 times as high [95% 
ei: 1.01 , 1.77] among obese women as normal weight women (Table 2.6). Underweight, 
WHR and we did not appreciably affect the risk of SAB earlier than 8 weeks of 
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gestation. In contrast, obese women had no appreciable difference in risk of SAB by 8 
weeks of gestation or later (HR: 0.99; [95% CI: 0.62, 1.59]) relative to normal weight 
women. Underweight was not materially associated with risk of SAB occurring at 8 
gestational weeks or later (HR: 1.10; [95% CI: 0.72, 1.68]). The effects ofheight were 
similar for early and late losses. Higher WC and WHR were associated with lower risks 
of SAB at 8 weeks or later, but the magnitude of the associations was not consistent 
across categories (Table 2.6). 
Results for BMI stratified by TTP, parity, maternal age, and menstrual cycle 
regularity are shown in Table 2.7. The association between obesity and risk of SAB was 
stronger among women with short TTPs, women aged <30 years, and women with 
regular menstrual cycles. The HRs for SAB were 1.17 among underweight parous 
women ([95% CI: 0.81, 1.69]) and 0.92 among underweight nulliparous women ([95% 
CI: 0.70, 1.20]). Results for analyses ofWHR, WC, height, and tendency to gain weight 
in relation to SAB did not differ much across strata ofTTP, parity, maternal age, or cycle 
regularity (Table 2.7). 
2.4 DISCUSSION 
In this prospective cohort study of Danish pregnancy planners, we observed a 
small increased risk of SAB among obese women relative to normal weight women, 
especially for SAB occurring before 8 completed weeks of gestation. Increased WHR 
and increased height were associated with a small decreased risk of SAB. Underweight, 
WC, and location of weight gain were not materially associated with SAB risk. 
Our results for obesity agree with previous studies that have shown increased risk 
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of SAB among overweight and obese women.7'8'39-42 However, our study did not 
corroborate reports of an increased risk among underweight women,7'9 using two 
different cut-points for underweight (18 .5 and 20 kg/m2) . Our fmding of an increased 
risk of SAB before 8 weeks of gestation among obese women agrees with one study,40 
but differs from another/ possibly because different definitions of early SAB (6-12 
weeks gestation40 and <14 weeks gestation7) were used in each study. Differential left-
truncation bias, which is common in other studies of SAB that recruit women who are 
already pregnant,43 is not a problem in our study because we enrolled women prior to 
conception. No previous study has investigated WHR, WC, height, and body fat 
distribution. 
The present study did not collect daily readings of human chorionic gonadotropin 
(hCG), the earliest biologic marker of implantation, so it is inevitable that some early 
SABs were not identified. This limitation is common to most SAB studies. Missing early 
losses would have induced bias if body size affected early losses differently than later 
losses. It is also possible that women who were lost to follow-up or became pregnant a 
long time after completing Snart Gravid had a missed SAB or a change in body size 
before the index pregnancy that was included in our study. The proportion of missed 
SABs is expected to be smaller within a population of pregnancy planners than among 
the general population because pregnancy planners are presumably more aware of their 
menstrual cycles. In support of this theory, 96% of the Snart-Gravid participants who 
conceived used home pregnancy tests to confirm their pregnancies44 
Errors in fetal measurements of gestational age are likely, especially for obese 
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women among whom gestational age tends to be underestimated.45•46 In this study, 
gestational age was measured two ways, depending on the source of the information. For 
SABs identified by questionnaire only, gestational age was measured using date ofLMP. 
For all registry-confirmed SABs, gestational age was measured using early ultrasound 
fetometry or LMP. Ultrasounds at 17-18 gestational weeks have been found to be less 
accurate in obese women,45•46 which would lead to distortions in the association between 
obesity and timing of SAB. Among women who self-reported SABs, gestational age was 
based on date of the last menstrual period. This assessment can also be inaccurate among 
women with irregular cycles. Inaccurate gestational age may have led to either an 
overestimation or underestimation of the association, depending on how the date of 
conception was misclassified. In Denmark, the cut-point used to define SAB clinically is 
22 weeks. Because many studies have measured SAB only up to 20 weeks, we re-
analyzed the results censoring at 20 weeks and found little difference in the effect 
estimates, likely because only one SAB occurred after 20 weeks. 
Body size measurements were self-reported by participants, thus enhancing the 
potential for misclassification of the exposure. In a previous investigation based on this 
cohort, 47 high concordance was found between height and weight measurements reported 
by participants and corresponding measurements taken during a physical exam (r=0.96). 
Self-reported data on WC and WHR were not validated in our cohort but validation 
studies of similar populations have found that women tend to underestimate these 
measurements,48 though secondary analyses among women who used a tape measure in 
our cohort produced similar results. Tendency to gain weight was also not verified, but 
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one stud/9 found that self-reported female body shape was consistent with 
anthropometric measures used to assess fat distribution. Exposure misclassification in 
this study is expected to be nondifferential and bias associations for the extreme 
categories toward the null. 
Since the outcome data were collected from two data sources, independent of 
exposure information, we do not believe that dependent misclassification between 
exposure and outcome is a major concern. Nevertheless, because the exposure and 
covariates were collected using a self-administered questionnaire, there is a possibility 
that misclassification of these variables may be correlated with each other and lead to 
dependent misclassification and residual confounding. 34 
The observed association between high BMI and increased risk of SAB is 
biologically plausible. Increased total protein, leptin, apolipoprotein Al, and by-products 
of chronic inflammation and dyslipidemia have been found in the follicular 
microenvironment of obese women compared with normal women, and they may affect 
the development of a viable fetus. 18 '50'51 A study of placental tissues showed that 90.9% 
of SAB placentas had high bacteria levels vs. only 16.7% of control placentas, a 
difference that could heighten inflammatory immune responses and lead to SAB 16 but 
also may be caused by SAB. Decreased levels of estradiol have been found among 
reproductive-aged women with both very low and very high percentages of body fat. 52 
Lower levels of estradiol during the menstrual cycle have been associated with lower 
pregnancy rates53 and it is plausible that low estradiol levels negatively affect developing 
fetuses. In contrast, taller women have been found to have higher follicular-phase plasma 
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estradiol levels compared with shorter women which may explain the observed decrease 
in SAB risk. 54 Increased abdominal obesity has been shown to be associated with 
decreased levels of sex hormone binding globulin (SHBG), 12' 13'55 independent of BMI, 
which may be associated with lower levels of estradiol. Residual confounding may be 
also contributing to the observed decreased risk of SAB among taller women. Other 
studies have found strong relationships between female height and higher socioeconomic 
status, education, and other risk factors associated with both obesity and increased SAB 
risk. 56-58 
In summary, we found that obesity was associated with an increased risk of SAB, 
and the association was stronger for early pregnancy losses (before 8 weeks of gestation). 
Increasing WHR was associated with a slight decrease in risk of SAB. The association 
was mainly driven by a higher risk in the women with the smallest WHR; differences in 
the HRs across the higher categories of WHR were not as pronounced. Increasing height 
was also associated with a decrease in SAB risk. WC, underweight, and tendency to gain 
weight were not appreciably associated with SAB in this cohort. 
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Table 2.1 Distribution of gestational age of SABs by identification source 
Snart Gravid Both SG and Missing from Gestational age Registry only 
follow-up only registry 
registry, assumed 
(weeks) N=192 SABb N=264" N=113 
N=163 
4 4 (2. 1) 59 (22.4) 8 (7.1) 10 (6.1) 
5 13 (6.8) 64 (24.2) 16 (14.2) 11 (6.8) 
6 42 (21.9) 46 (17.4) 23 (20.4) 36 (22.1) 
7 37 (19.3) 33 (12.5) 28 (24.8) 40 (24.5) 
8 20 (10.4) 22 (8 .3) 18 (15.9) 36 (22.1) 
9 10 (5.2) 13 (4.9) 7 (6.2) 21 (12.9) 
10 17 (8 .9) 8 (3.0) 7 (6.2) 6 (3.7) 
11 23 (12.0) 8 (3 .0) 4 (3.5) 3 (1.8) 
12 12 (6.3) 7 (2.7) 2 (1.8) 
13 3 (1.6) 1 (0.4) 
14 2 (1.0) 3 (1.1) 
15 
16 2 (1 .0) 
17 1 (0.5) 
18 4 (2.1) 
19 1 (0.5) 
20 
21 1 (0.5) 
"The SG follow-up questionnaires are less likely to identify later losses (>8 weeks of gestation) because they are conducted every two 
months 
bGestational age for participants who were completely missing from the registry were multiply imputed, frequencies presented are from 
the first imputation dataset. 
Table 2.2. Age-adjusted distribution of b aseline characteristicsa of 5132 women from the Snart Gravid study by body mass 
index and waist-to-hip ratio 
Body Mass Index (kg/m' ) Waist-to-Hip Ratio 
<20 20-24.9 25-29.9 >30 <0.75 0.75-0.79 0.80-0.84 ~0.85 
Parity(%) 
Nulliparous 68.6 71.5 61.3 54.8 76.6 72.5 64.0 58.3 
1 birth 24.2 21.5 28.6 34.7 18.6 19.4 26.8 32.9 
~2 births 7.2 7.0 10.1 10.5 4.9 8.1 9.3 8.8 
Vocational training/education (%) 
No vocational training 13.1 10.6 14.0 16.4 10.6 10.5 13 .1 14.7 
Semi-skilled/basic training 12.9 14.6 17.4 21.0 11.9 15.2 15.7 18.6 
Higher education (:<:::4 years) 47.0 48 .7 54.8 53 .3 47.3 50.1 49.7 52.2 
Higher education (>4 years) 27.0 26.2 13.9 9.3 30.2 24.2 21.5 14.6 
Smoking status(%) 
Non-smokers 79.0 81.5 78.4 78.7 82.0 83.8 78.4 77 .0 
<1 0 cigarettes/day 10.6 10.3 10.6 9.7 10.8 8.7 10.8 10.8 
~ 10 cigs/day 10.4 8.2 11.0 11.6 7.2 7.5 10.8 12.2 
Caffeine consumption(%) 
N <100 mg/day 48.0 45 .6 47.1 54.1 44.8 48.7 46.6 48.2 0 
100-199 mg/day 17.3 17.0 18.0 17.8 18.1 16.7 16.4 18.2 
200-299 mg/day 13.2 14.0 14.3 10.1 15.1 13.7 12.8 12.7 
~300 mg/day 21.5 23.4 20.6 17.9 22.0 21.0 24.3 20.9 
Alcohol categories(%) 
0 drinks per week 30.0 28.2 34.0 40.0 28.5 31.6 30.1 33.2 
1-2 drinklwk 30.3 29.9 29.1 28 .3 32.1 28.9 29.5 28.6 
3-6 drinks/wk 30.1 30.2 26.7 22.7 29.2 29.6 28.6 27.6 
~7 drinks/wk 9.9 11.6 10.2 9.0 102 10.1 11.8 10.7 
METs categories (%) 
< IOMETs 14.5 12.6 19.4 21.1 12.8 13.1 15.9 19.6 
10-1 9 METs 30.7 30.9 33.4 38.4 30.4 32.8 33.1 32.6 
20-39 METs 35.6 37.8 34.2 26.6 36.9 36.1 35.1 33.9 
~40METs 19.2 18.7 13.1 11.0 19.9 18.0 16.0 13.9 
Regular menstrual cycles (%) 71.1 76.6 77.0 70.4 76.7 75.0 75.1 73.8 
Time to re nanc > 6 months %) 55.6 52.8 58.7 65.2 52.6 53 .6 54.9 61.1 
"Characteristics are presented as percentages within levels of BMI and WHR based on the first imputation dataset, and are standardized to 
age distribution of cohort at baseline 
Table 2.3. Numbera of spontaneous abortions and gestational weeks at risk by maternal age and body mass index 
Body Mass Index (kg/m) 
Age (Years) <20 20-24 25-20 ~30 Total 
~20 
SAB 4 7 4 4 19 
Gestational weeks 523 1101 476 339 2439 
Rate/1000 GW 7.6 6.4 8.4 11.8 7.8 
21 -24 
SAB 18 44 16 16 94 
Gestational weeks 2634 7248 3505 1914 15301 
Rate/1 000 GW 6.8 6. 1 4.6 8.4 6.1 
25-28 
SAB 39 123 41 42 245 
Gestational weeks 5584 19678 7055 3916 36233 
Rate/1000 GW 7.0 6.3 5.8 10.7 6.8 
29-32 
SAB 29 126 41 23 219 
N Gestational weeks 4112 16647 5977 3414 30150 
....... Rate/1000 GW 7.1 7.6 6.9 6.7 7.3 
33-36 
SAB 13 69 24 14 120 
Gestational weeks 1620 6770 2915 1440 12745 
Rate/ 1000 GW 8.0 10.2 8.2 9.7 9.4 
~37 
SAB 5 16 9 5 35 
Gestational weeks 519 1515 766 611 3411 
Rate/1000 GW 9.6 10.6 11.7 8.2 10.3 
Age-Standardized rate/1000 GW 7.2 7.3 6.5 9.0 
Age-Standardized rate difference 0.0 [ret] -0.8 1.7 
(95% CI) -1.6, 1.5 -2.0, 0.6 -0.2, 3.6 
Age-Standardized rate ratio 0.99 [ret] 0.90 1.23 
{95% CI) 0.80, 1.23 0.73, 1.09 0.99, 1.54 
aFrom the ftrst imputation dataset 
N 
N 
Table 2.4 Hazard ratios for the association between body size and SAB when adjusting for potential confounders measured at 
baseline 
Exposure N Crude Adjusted model Adjusted model with 
SABa Total GWs" HR HR [95% CI]b body size HR [95% CI]" 
Body Mass Index (kg/m2) 
<20 108 14992 0.99 1.00 [0.81 , 1.24] 0.93 [0.73 , 1.19] 
20-24 385 52959 1. 00 [Reference] 
25-29 135 20694 0.90 0.90 [0.73, 1.09] 0.94 [0.71 , 1.23] 
?:30 104 11634 1.22 1.23 [0.98, 1.54] 1.26 [0.87, 1.83] 
Waist circumference 
<75 em 199 25500 1.00 [Reference] 
75-79 em 165 23120 0.94 0.92 [0.73, 1.16] 0.91 [0.71 , 1.17] 
80-86 em 150 23115 0.85 0.82 [0.65, 1.03] 0.80 [0.61 , 1.06] 
?:87 em 218 28544 1.00 0.97 [0.75, 1.25] 0.88 [0.57, 1.36] 
Waist-to-hip ratio 
<0.75 186 21024 1.00 [Reference] 
0.75-0.79 175 24316 0.86 0.85 [0.67, 1.06] 0.84 [0.67, 1.06] 
0.80-0.84 166 24695 0.79 0.76 [0.58, 1.00] 0.75 [0.57, 0.99] 
?:0.85 205 30244 0.85 0.81 [0.63, 1.05] 0.78 [0.59, 1.03] 
Height 
<166 em 233 31550 1.00 [Reference] 
166-169 em 180 21151 1.15 1.14 [0.93, 1.38] 1.12 [0.92, 1.37] 
170-173cm 171 23058 1.00 0.99 [0.81 , 1.21] 0.97 [0.79, 1.18] 
?:174 em 148 24520 0.82 0.81 [0.66, 1.00] 0.79 [0.63, 0.98] 
Location of weight gain 
Equally all over 198 27464 1.00 [Reference] 
Waist/ stomach 300 40975 1.01 1.01 [0.84, 1.21] 1.02 [0.85, 1.23] 
Hips/ thighs 198 26754 1.03 1.03 [0.84, 1.26] 1.04 [0.85, 1.27] 
Does not gain weight 27 4204 0.88 0.88 [0.59, 1.32] 0.89 [0.59, 1.35] 
Chest/ shoulders 9 882 1.18 1.15 [0.50, 2.65] 1.15 [0.50, 2.65] 
•Frequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted for maternal age, physical activity, caffeine consumption, parity, vocational training/education, alcohol consumption, and smoking. 
cAdjusted for variables in footnote band body size (BMI model adjusted for waist circumference, height model adjusted for weight; all other models 
adjusted for BMI.). 
N 
w 
Table 2.5 Complete case analysis using unimputed waist and hip measures compared with analyses among women who used a 
tape measure and multiple imputation analysis 
Waist 
circumference 
<75 em 
75-79 em 
80-86 em 
2:87 em 
Waist-to-hip ratio 
<0.75 
0.75-0.79 
0.80-0.84 
>0.85 
Total 
N(%)a 
586 (30.5) 
459 (23 .9) 
408 (21.3) 
466 (24.3) 
Complete Case a, b 
HR [95% CI] 
1.00 [Reference] 
0.98 [0.72, 1.34] 
0. 79 [0.56, 1.12] 
0.92 [0.67, 1.28] 
Total 
N(%t. 
565 (30.6) 
438 (23.7) 
397 (21.5) 
447 (24.2) 
Used a T t 1 Imputed (5 
. b oa d ) 
measurmg tape N ('X t atasets 
HR [95% CI] 0 HR [95% CI] b 
1.00 [Reference] 
1.01 [0.74, 1.39] 
0.80[0.57, 1.13] 
0.87 [0.63, 1.22] 
1309 (25 .5) 
1179 (23.0) 
1174 (22.9) 
1470 (28.6) 
1.00 [Reference] 
0.92 [0.73, 1.16] 
0.82 [0.65, 1.03] 
0.97 [0.75 , 1.25] 
416 (21.7) 1.00 [Reference] 391 (21.2) 1.00 [Reference] 1090 (21.2) 1.00 [Reference] 
540 (28 .1) 0.77 [0.56, 1.06] 521 (28 .2) 0.76 [0.55, 1.06] 1251 (24.4) 0.85 [0.67, 1.06] 
455 (23.7) 0.66 [0.47, 0.94] • 443 (24.0) 0.62 [0.43, 0.89] 1247 (24.3) 0.76 [0.58, 1.00] 
508 (26.5) 0.83 [0 .60, 1.16] 492 (26.6) 0.80 [0.57, 1.11] 1544 (30.1) 0.81 [0.63 , 1.05] 
a From first imputation dataset 
b Adjusted for maternal age, physical activity, caffeine consumption, parity, vocational training/education, alcohol consumption, and 
smoking 
Table 2.6 Hazard ratios for the association of body size with early (<8 gestational weeks) and late SAB 
Early SAB <8 weeks gestation Late SAB 2:8 weeks 
N Total Adjusted model Adjusted model N Total Adjusted model Adjusted model 
SABa aw• Crude HR [95% CI]b with body size SAB" aw• Crude HR [95% CI]b with body size HR [95% Cl]0 HR [95% ere 
Body Mass Index 
(kg/m2) 
<20 67 414 0.95 0.95 [0. 70, 1.28] 0.92 [0.67' 1.26] 41 14578 1.06 1.10 [0. 72, 1.68] 0.95 [0.58, 1.58] 
20-24.9 255 1685 1.00 [Reference] 130 51274 1.00 [Reference] 
25-29.9 78 494 0.84 0.82 [0.62, 1.10] 0.87 [0.58, 1.29] 57 20200 1.02 1.04 [0.70, 1.54] 1.07 [0.69, 1.67] 
2:30 80 502 1.36 1.34 [1.01, 1.77] 1.41 [0.84, 2.35] 24 11132 0.95 0.99 [0.62, 1.59] 0.99 [0.56, 1.74] 
Waist circumference 
<75 em 121 758 1.00 [Reference] 78 24742 1.00 [Reference] 
75-79 em 114 754 1.04 1.03 [0.78, 1.38] 1.02 [0.77, 1.35] 51 22366 0.78 0.74 [0.47, 1.16] 0.73 [0.44, 1.19] 
80-86 em 97 679 0.88 0.87 [0.66, 1.14] 0.86 [0.63, 1.18] 53 22436 0.78 0.74 [0.49, 1.10] 0.71 [0.43, 1.17] 
2:87cm 148 904 1.08 1.04 [0.79, 1.38] 0.91 [0.54, 1.53] 70 27640 0.87 0.85 [0.55, 1.30] 0.81 [0.44, 1.50] 
Waist-to-hip ratio 
<0.75 115 688 1.00 [Reference] 71 20336 1.00 [Reference] 
N 0.75-0.79 116 812 0.93 0.92 [0.68, 1.25] 0.92 [0.67, 1.25] 59 23504 0.75 0.72 [0.47, 1.10] 0.72 [0.47, 1.10] 
.:::.. 0.80-0.84 110 693 0.80 0.78 [0.54, 1.11] 0. 76 [0.53, 1.1 0] 56 24002 0.78 0. 73 [0.48, 1.11] 0.73 [0.48, 1.11] 
2:0.85 139 902 0.92 0.89 [0.66, 1.19] 0.84 [0.62, 1.16] 66 29342 0.72 0.69 [0.46, 1.02] 0.68 [0.45, 1.02] 
Height 
<166 em 163 1081 1.00 [Reference] 70 30469 1.00 [Reference] 
166-169 em 112 709 1.00 1.01 [0.77, 1.31 ] 1.00 [0.73, 1.31] 68 20442 1.49 1.45 [0.99, 2.12] 1.41 [0.96, 2.08] 
170-173 em 107 666 0.89 0.89 [0.69, 1.15] 0.87 [0.67, 1.14] 64 22392 1.28 1.23 [0.85, 1.79] 1.18 [0.81 , 1.73] 
2: 174 em 98 639 0.78 0.78 [0.60, 1.02] 0.77 [0.58, 1.02] 50 23881 0.92 0.88 [0.59, 1.33] 0.83 [0.54, 1.28] 
Location of weight gain 
Equally all over 125 810 1.00 [Reference] 73 26654 1.00 [Reference] 
Waist/stomach 191 1259 1.02 1.02 [0.81 ' 1.28] 1.04 [0.83, 1.32] 109 39716 0.99 0.99 [0.73 , 1.35] 0.99 [0. 73 , 1.35] 
Hips/thighs 142 882 1.13 1.14 [0.87, 1.50] 1.17 [0.88, 1.54] 56 25872 0.84 0.84 [0.56, 1.25] 0.83 [0.55, 1.26] 
Does not gain weight 16 107 0.83 0.82 [0.45, 1.50] 0.84 [0.45, 1.57] 11 4097 0.95 0.98 [0.45, 2. 16] 0.95 [0.42, 2.13] 
Chest/shoulders 6 37 1.10 1.06 0.34, 3.31 ] 1.07 0.35, 3.31 ] 3 845 1.29 1.29 0.39, 4.19] 1.27 [0.39, 4.17 
"Frequencies and gestational weeks (GW) from the first imputation dataset 
hAdjusted for maternal age, physical activity, caffeine consumption, parity, vocational training/education, alcohol consumption, and smoking. 
c Adjusted for variables in footnote b and body size (BMI model adjusted for waist circumference, height model adjusted for weight; all other models 
adjusted for BMI). 
Table 2.7. Hazard ratios for the association between body size and SAB, stratified by 
time to pregnancy, parity, maternal age, and menstrual cycle regularity 
Body Size N Total TTP <6 monthsb N Total TTP 2:6 monthsb Characteristics SABa GWsa SABa Gws• 
Body mass index 
(kg/m2) 
<20 50 6617 1.08 [0.79, 1.48] 58 8375 0.91 [0.68, 1.23] 
20-24 177 25128 1.00 [Reference] 208 27831 1.00 [Reference] 
25-29 43 8704 0.70 [0.50, 0.98] 92 11990 1.02 [0.80, 1.31] 
2:30 46 3939 1.65 [1.18, 2.31] 58 7695 1.02 [0.76, 1.38] 
Waist 
circumference 
<75 em 86 11768 1.00 [Reference] 113 13732 1.00 [Reference] 
75-79 em 79 11414 0.90 [0.64, 1.26] 86 11706 0.95 [0.68, 1.35] 
80-86 em 65 10379 0.80 [0.55, 1.17] 85 12736 0.84 [0.62, 1.15] 
2:87cm 86 10827 0.99 [0.71, 1.39] 132 17717 0.97 [0.68, 1.40] 
Waist to hip ratio 
<0.75 85 10048 1.00 [Reference] 101 10976 1.00 [Reference] 
0.75-0.79 78 11325 0.80 [0.56, 1.12] 97 12991 0.89 [0 .64, 1.23] 
0.80-0.84 73 11209 0.71 [0.49, 1.02] 93 13486 0.79 [0.56, 1.13] 
2:0.85 80 11806 0. 78 [0.54, 1.13] 125 18438 0.83 [0.59, 1.19] 
Height 
<166 em 95 13642 1.00 [Reference] 138 17908 1.00 [Reference] 
166-169 em 71 9298 1.09 [0.80, 1.49] 109 11853 1.18 [0.92, 1.52] 
170-173 em 80 10236 1.13 [0. 84, 1.53] 91 12822 0.92 [0.71, 1.21] 
2:174 em 70 11212 0.91 [0.66, 1.24] 78 13308 0.76 [0.58, 1.01] 
Location of 
weight gain 
Equally all over 90 12155 1.00 [Reference] 108 15309 1.00 [Reference] 
Waist/stomach 114 17683 0.84 [0 .64, 1.11] 186 23292 1.16 [0.91 , 1.47] 
Hips/thighs 96 12442 1.05 [0. 78, 1.40] 102 14312 1.01 [0. 77' 1.33] 
Does not gain 11 1693 0.85 [0.45 , 1.59] 16 2511 0.91 [0.54, 1.54] 
weight 
Chest/shoulders 5 415 1.06 [0.24, 4.71] 4 467 1.21 [0.40, 3 .63] 
•Frequencies and gestational weeks (GW) from the first imputation dataset 
b Adjusted for maternal age, physical activity, caffeine consumption, parity, vocational 
training/education, alcohol consumption, and smoking. 
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Table 2.7 continued. Hazard ratios for the association between body size and SAB, 
stratified by parity 
Body Size N Total Nulliparousb N Total Parousb Characteristics SAB" GWsa SABa GWsa 
Body mass index 
(kg/m2) 
<20 69 10661 0.92 [0.70, 1.20] 39 4331 1.17 [0.81, 1.69] 
20-24 268 37816 1.00 [Reference] 117 15143 1.00 [Reference] 
25-29 80 12647 0.89 [0.69, 1.15] 55 8047 0.90 [0.65, 1.25] 
2:30 56 6455 1.24 [0 .93, 1.67] 48 5179 1.22 [0.87, 1.73] 
Waist circumference 
<75 em 144 20242 1.00 [Reference] 55 5258 1.00 [Reference] 
75-79 em 112 16472 0.96 [0.74, 1.26] 53 6648 0.81 [0.52, 1.27] 
80-86 em 95 14925 0.89 [0.68, 1.18] 55 8190 0.66 [0.40, 1.08] 
2:87cm 122 15940 1.06 [0.80, 1.41] 96 12604 0.80 [0.53, 1.21] 
Waist to hip ratio 
<0.75 144 16632 1.00 [Reference] 42 4392 1.00 [Reference] 
0.75-0.79 110 17908 0.78 [0.58, 1.03] 65 6408 1.04 [0.69, 1.57] 
0.80-0.84 103 15577 0.76 [0.53, 1.08] 63 9118 0. 79 [0.48, 1.30] 
2:0.85 116 17462 0.83 [0.62, 1.13] 89 12782 0.82 [0.55, 1.22] 
Height 
<166 em 157 20732 1.00 [Reference] 76 10818 1.00 [Reference] 
166-169 em 109 14385 0.99 [0.78, 1.27] 71 6766 1.45 [1.05, 2.02] 
170-173 em 114 15929 0.94 [0. 73 , 1.19] 57 7129 1.12 [0.79, 1.58] 
2:174 em 93 16533 0.74 [0.57, 0.96] 55 7987 0.92 [0.65, 1.31] 
Location of weight 
gam 
Equally all over 123 18133 1.00 [Reference] 75 9331 1.00 [Reference] 
Waist/stomach 193 27539 1.02 [0.81, 1.28] 107 13436 0.98 [0.73, 1.32] 
Hips/thighs 132 18377 1.06 [0.83, 1.36] 66 8377 0.96 [0.69, 1.34] 
Does not gain weight 21 2883 1.07 [0.67' 1. 70] 6 1321 0.54 [0.23, 1.25] 
Chest/shoulders 4 647 0.90 [0.30, 2.71 ] 5 235 1.82 [0.55, 6.03] 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted for maternal age, physical activity, caffeine consumption, parity, vocational 
training/education, alcohol consumption, and smoking. 
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Table 2 .7 continued. Hazard ratios and 95% confidence intervals the association between 
body size and SAB~ stratified b~ age 
Body Size N Total Age <30b N Total Age~ 30b Characteristics SAB" GWs" SAB" GWs" 
Body mass index 
(kg/m2) 
<20 69 9978 1.13 [0.86, 1.49] 39 5014 0.85 [0.60, 1.21] 
20-24 203 33340 1.00 [Reference] 182 19619 1.00 [Reference] 
25-29 76 12789 0.98 [0.75, 1.28] 59 7905 0.80 [0.59, 1.08] 
~30 67 7373 1.53 [1.15, 2.03] 37 4261 0.92 [0.64, 1.32] 
Waist 
circumference 
<75 em 123 17782 1.00 [Reference] 76 77 18 1.00 [Reference] 
75-79 em 93 14693 0.92 [0.67, 1.26] 72 8427 0.95 [0.61, 1.48] 
80-86 em 81 13736 0.85 [0.61, 1.1 9] 69 9379 0.80 [0.53, 1.20] 
~87cm 118 17269 0.99 [0.73, 1.35] 100 11275 0.99 [0.64, 1.52] 
Waist to hip ratio 
<0.75 117 14489 1.00 [Reference] 69 6535 1.00 [Reference] 
0.75-0.79 102 15500 0.86 [0.65, 1.13] 73 8816 0.85 [0.59, 1.23] 
0.80-0.84 92 14974 0.76 [0.54, 1.08] 74 9721 0.80 [0.55, 1.15] 
~0.85 104 18517 0.82 [0.58, 1.1 6] 101 11727 0.85 [0.56, 1.28] 
Height 
<166 em 147 20940 1.00 [Reference] 86 10610 1.00 [Reference] 
166-169 em 102 13640 1.05 [0.82, 1.36] 78 75 11 1.30 [0.95, 1.77] 
170-173 em 87 14540 0.86 [0.66, 1. 12] 84 8518 1.22 [0.90, 1.65] 
~174 em 79 14360 0.78 [0.60, 1.03] 69 10160 0.87 [0.63, 1.20] 
Location of 
weight gain 
Equally all over 113 17444 1.00 [Reference] 85 10020 1.00 [Reference] 
· Waist/stomach 170 26275 0.99 [0.77, 1.26] 130 14700 1.05 [0.79, 1.38] 
Hips/thighs 111 16591 1.02 [0.78, 1.33] 87 10163 1.03 [0.76, 1.39] 
Does not gain 16 2648 0.90 [0.53, 1.53] 11 1556 0.81 [0.43, 1.53] 
weight 
Chest/shoulders 5 522 1. 18 [0.36, 3.82] 4 360 1.15 [0.36, 3.69] 
•Frequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted for maternal age, physical activity, caffeine consumption, parity, vocational 
training/education, alcohol consumption, and smoking. 
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Table 2. 7 continued. Hazard ratios and 95% confidence intervals for the association 
between body size and SAB, stratified cycle regularity. 
Body Size N Total Regular Periodsb N Total Irregular Characteristics SABa GWsa SABa GWsa Periodsb 
Body mass index 
(kg/m2) 
<20 82 10464 1.06 [0.83, 1.36] 26 4528 0.83 [0.53, 1.30] 
20-24 298 40566 1.00 [Reference] 87 12393 1 . 00 [Reference] 
25-29 107 15931 0.91 [0.73, 1.14] 28 4763 0.83 [0.53, 1.28] 
2:30 82 8075 1.37 [1.06, 1.76] 22 3559 0.91 [0 .53, 1.47] 
· Waist circumference 
<75 em 154 18441 1.00 [Reference] 45 7059 1.00 [Reference] 
75-79 em 120 17892 0.85 [0.65, 1.12] 45 5228 1.19 [0.73, 1.95] 
80-86 em 119 17595 0.83 [0.64, 1.08] 31 5520 0.77 [0.44, 1.34] 
2:87cm 176 21108 1.03 [0. 78, 1.35] 42 7436 0.79 [0.48, 1.29] 
Waist to hip ratio 
<0.75 147 15982 1.00 [Reference] 39 5042 1.00 [Reference] 
0.75-0.79 132 18224 0.85 [0.65, 1.10] 43 6092 0.88 [0.56, 1.36] 
0.80-0.84 126 18587 0.77 [0.56, 1.06] 40 6108 0.73 [0.42, 1.24] 
2:0.85 164 22243 0.86 [0.63, 1. 18] 41 8001 0.65 [0.40, 1.07] 
Height 
<166 em 185 23322 1.00 [Reference] 48 8228 1.00 [Reference] 
166-169 em 135 16124 1.04 [0.83, 1.3 1] 45 5027 1.47 [0.97, 2.22] 
170-173 em 136 17401 0.98 [0.78, 1.22] 35 5657 1.00 [0.64, 1.56] 
2:174 em 113 18189 0.78 [0.61 , 0.98] 35 6331 0.94 [0.60, 1.46] 
Location of weight 
gam 
Equally all over 147 20481 1.00 [Reference] 51 6983 1.00 [Reference] 
Waist/stomach 245 29795 1. 12 [0.91, 1.37] 55 11180 0.70 [0.48, 1.04] 
Hips/thighs 147 20804 0.99 [0.79, 1.25] 51 5950 1.16 [0.78, 1.73] 
Does not gain 22 3277 0.92 [0.59, 1.44] 5 927 0. 78 [0.31' 1.97] 
weight 
Chest/shoulders 8 679 1.38 [0.55, 3.46] 1 203 0.57 [0.07, 4.52] 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted for maternal age, physical activity, caffeine consumption, parity, vocational 
training/education, alcohol consumption, and smoking. 
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Figure 2.1 Flow chart of pregnancies observed in Snart Gravid participants 
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Figure 2.2. Relationship between BMI and risk of SAB <22 weeks fitted by restricted 
cubic splines. 
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Reference level for the hazard ratio is a BMI of22 kg/m2 . The dotted lines represent the 
corresponding 95% confidence intervals. 
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3 CAFFEINE AND CAFFEINATED BEVERAGE CONSUMPTION AND 
SPONTANEOUS ABORTION 
3.1 INTRODUCTION 
Caffeine consumption has been hypothesized as a risk factor for SAB since the 
1980s 1 because it is associated with endogenous hormone levels2 and can cross the 
placenta.3 Pregnant women have a prolonged metabolism of caffeine (15.08 hour half-
life) compared with non-pregnant women ( 4.71 hour half-life) and fetuses have very slow 
elimination of caffeine, suggesting that maternal caffeine ingestion could increase fetal 
caffeine levels exponentially.4 Furthermore, some2'5'6 but not alf studies have shown that 
consumption of caffeine alters endogenous hormone levels. Caffeine has been found to 
be inversely related to levels of estradiol and progesterone during the luteal phase of the 
menstrual cycle.2'5'6 Coffee consumption has also been linked to increases in sex hormone 
binding globulin (SHBG).5 These hormonal changes related to caffeine consumption may 
affect the risk of SAB. 
Published results of the association between caffeine and SAB risk have been 
conflicting,8-21 likely due to differences in study design and populations, outcome 
ascertainment, and exposure misclassification. We examined the risk of SAB in relation 
to preconception and early pregnancy (EP) consumption of caffeine and caffeinated 
beverages among women enrolled in a prospective cohort study in Denmark. 
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3.2 METHODS 
3.2.1 Data collection 
The Snart-Gravid study (SG) is an Internet-based prospective cohort study of time 
to pregnancy. Recruitment began in 2007 when an advertisement was placed on a Danish 
health-related website (www.netdoktor.dk) and a coordinated media strategy was 
launched. 22-24 Enrollment and primary data collection were conducted via a self-
administered questionnaire on the study website (www.snart-gravid.dk). Contact with 
participants was maintained through the study website and e-mail. 
Before enrollment, participants completed a consent form and an online screening 
questionnaire to verify eligibility. Women eligible to participate in Snart Gravid were 
aged 18-40 years, residents of Denmark, in a stable relationship with a male partner, not 
using fertility treatment, and trying to become pregnant. Participants were required to 
provide a valid e-mail address and their Civil Personal Registration (CPR) number, a 
unique 1 0-digit personal identification number assigned to each Danish resident. After 
38 months of recruitment, 5,921 women had enrolled in the study. The study was 
approved by the Danish Data Protection Board and the Institutional Review Board of 
Boston University Medical Campus. 
The baseline questionnaire collected information on demographics, lifestyle and 
behavioral factors , and reproductive and medical history. Participants were contacted 
every two months by e-mail with a reminder to fill out a follow-up questionnaire. 
Follow-up questionnaires assessed changes in exposures and pregnancy status, including 
whether any clinically-recognized pregnancy losses had occurred. Follow-up continued 
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until conception occurred or for a maximum of 12 months. Women who were pregnant 
at the time of the follow-up questionnaire were asked to complete an early pregnancy 
questionnaire to assess any changes in exposures since conception as well as pregnancy 
symptoms. 
To obtain information on pregnancy outcomes among women in the cohort, we 
linked each woman's CPR number to the Danish National Registry of Patients (DNRP) 
and Danish Medical Birth Registry (DMBR) records through 2012. The DNRP provides 
information on hospital and outpatient encounters (including SAB and therapeutic 
abortion (TAB)) and the DMBR gives information on live and still births after 22 
gestational weeks (GW).Z5'26 Pregnancy outcomes occurring after the baseline enrollment 
date in the Snart Gravid cohort were identified using ICD-1 0 codes (D003 for SAB and 
D004 forT AB) in the DNRP. A validation study of DNRP data found that 30% of self-
reported SABs were not registered in the DNRP;25 however, this study examined records 
from 1991-1995, before the registry started to include data from outpatient clinics 
(2:1995). Another study that compared the DNRP with data from individual medical 
records found a positive predictive value of98.7%.26 
3.2.2 Assessment of caffeine and caffeinated beverage consumption 
Servings per week of coffee (decaf and caffeinated; 250 m1 cup), tea (herbal/green 
and black; 250 ml cup), and cola (regular and diet; 500 ml bottle) were reported on the 
baseline, follow-up, and early pregnancy questionnaires. From these reports, the total 
amount of caffeine from beverages consumed per week, both preconception and during 
early pregnancy, was determined using the following formula based on milligrams (mg) 
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of caffeine per serying of each beverage as estimated by previous laboratory 
measurements27 : Total caffeine= caffeinated coffee (141 mg) +decaffeinated coffee (5 
mg) +black tea (56 mg) +regular cola (51 mg) +diet cola (66 mg). Because the 
questionnaire did not separate consumption of herbal and green tea we did not include it 
in our main caffeine formula. Daily servings of each beverage were also considered 
individually in the analyses. The preconception exposures analyzed in this manuscript 
represent the values of the caffeinated beverages reported on the most recent 
questionnaire completed by the participant. 49% of caffeine measurements were from a 
follow-up questionnaire and 51% were from the baseline questionnaire. The median time 
between the measurement of caffeine and conception was 29 days. 
3.2.3 Assessment of spontaneous abortion 
The outcome of interest was SAB. Women who experienced a pregnancy loss 
were asked to report the date of the loss and how long the pregnancy lasted (in weeks 
since the last menstrual period). The DNRP provided information on occurrences of 
SAB up to 22 gestational weeks and any TAB, the dates ofthese events, and the 
gestational age at which the pregnancy ended, as measured by ultrasound fetometry. For 
pregnancy losses recorded in both the registry and on a questionnaire, we used data from 
the DNRP (based on either early ultrasound fetometry or LMP) to measure gestational 
week of pregnancy loss. In Denmark, the first pregnancy-related ultrasound is around 12 
weeks of gestation so gestational ages of SABs after this time are likely based on 
ultrasound. For SABs reported only on a Snart Gravid follow-up questionnaire, 
gestational age was calculated as the number of weeks from the last menstrual period to 
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the date of pregnancy loss, rounded to the nearest whole week. Among the women who 
had a SAB reported in both sources, the correlation between gestational weeks reported 
on an SG questiorinaire and in the registry was 0. 71. The mean reported gestational age 
from SG was slightly lower 7.2 vs. 7.3 weeks in the registry. 
There were 163 women who reported a pregnancy on a Snart Gravid follow-up 
questionnaire but did not have any data from that pregnancy recorded in either the DNRP 
or the DMBR. For this analysis, we assumed that these women had an early SAB. We 
used multiple imputation to impute a gestational age :S12 weeks for each of these 
presumed SABs. Sensitivity analyses in which we excluded these pregnancies produced 
similar results (Appendix Table 2). 
3.2.4 Assessment of confounders 
Data on maternal age, parity, smoking status, prior SAB, alcohol consumption, 
physical activity, height and weight, and vocational training/education were self-reported 
on the baseline questionnaire. We estimated total metabolic equivalents (METs) per 
week by summing the METs from moderate physical activity (hours per week multiplied 
by 3.5 METs) and vigorous exercise (hours per week multiplied by 7.0 METs).28 Body 
mass index (BMI) was calculated as kg/m2 and was categorized as follows: <20, 20-24, 
25-29, ;:::::30. Smoking status, and alcohol consumption were updated on all subsequent 
follow-up questionnaires, including the early pregnancy questionnaire. 
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3.2.5 Study population 
The present analysis was restricted to women who conceived a clinically-
recognized pregnancy after emollment in the cohort. Only the first pregnancy after 
emollment in the study was included because we believe that exposure information for 
subsequent pregnancies would be misclassifled. We excluded 126 women because they 
were not living in Denmark during follow-up, 10 women because they did not provide a 
valid CPR, and 653 (11 %) women who did not conceive during the follow-up period (as 
indicated by the absence of pregnancy data on the follow-up questionnaires, the DNRP, 
and the DMBR) (See Figure 2.1). 
3.2.6 Data analysis 
We assessed the relationship between total caffeine consumption and individual 
consumption of caffeine-containing beverages and SAB separately during preconception 
and early pregnancy using a time-to-event analysis. Time to SAB was measured in 
gestational weeks. There are no standard or clinical cut points for caffeine exposure so 
we. categorized caffeine consumption as <100, 100-199, 200-299, and 2:300 mg per day 
based on a previous manuscript from the SG cohort29 and the highest categories 
examined in other caffeine and SAB studies. 10' 12' 15'30 The categories of daily caffeinated 
beverage consumption were 0, 1, 2, and 3 or more for coffee and 0, 1, and 2 or more for 
cola, black tea and herbal/green tea. We examined the shape and magnitude of the 
relation between daily caffeine consumption and SAB risk by using restricted cubic 
splines.31 
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We used Cox proportional hazards regression models, with gestational weeks as 
the time scale, to estimate hazard ratios (HRs) and 95% confidence intervals (Cis) for 
caffeine and caffeinated beverage consumption associated with SAB. We assumed that 
there was a true but unknown ordering for tied event times and used the "exact" option in 
SAS PROC PHREG/2 which takes into account all possible orderings of event times. 
Thus, the HR may be interpreted as the average per-week risk of SAB for the exposed 
category divided by the corresponding risk for the reference category. TABs were 
censored at the week of pregnancy termination and pregnancies lasting more than 22 
weeks were censored at 22 weeks. 
We selected potential confounders from a group of variables associated with SAB 
and the caffeine consumption in our data. We also considered covariates meeting the 
criteria for confounding based on a review of the literature and the assessment of causal 
graphs. 33 Covariates included for both the preconception and early pregnancy models 
were maternal age, cigarette smoking, previous SAB, parity, vocational 
training/education, and physical activity. The preconception model was also adjusted for 
alcohol consumption. Models for the individual caffeinated beverages (coffee, cola, 
herbal/green, and black tea) were mutually adjusted for each other (i.e., addition 
model).34 
In secondary analyses, we assessed whether the HRs were similar for women who 
differed by waiting time to pregnancy (TTP) for the index pregnancy (<6 vs. 2:6 months), 
smoking status (smoker vs. non-smoker), and body mass index (<25 kg/m2 vs. 2:25 
kg/m2). The etiology of pregnancy loss likely differs for early and late losses/5•36 
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especially by karyotype, we also examined the relationship between preconception 
caffeine and timing of losses (loss during <8 weeks gestation and loss during 2 8 weeks of 
gestation). The choice of 8 weeks as a cut point for evaluating the timing of pregnancy 
loss was based on karyotype data showing a higher proportion of chromosomal 
abnormalities prior to 8 weeks.37 Because it has been reported that women with viable 
pregnancies may experience more severe nausea symptoms and aversion to caffeinated 
beverages, we stratified our analyses on reported nausea during early pregnancy. We 
used substitution models to examine the association between changes in individual 
beverage consumption and SAB while holding total caffeine constant for each individual 
beverage.34 We also assessed the relationships between change in caffeine consumption 
(<300 mg/day=low/moderate, 2:300 mg/day=high) from preconception to early 
pregnancy. 
We used multiple imputation methods to impute missing covariate, exposure, and 
outcome information. 38 Covariate missingness ranged from 0% for maternal age, time to 
pregnancy, and smoking status to 44% for number of glasses of dessert wine during early 
pregnancy. 61% of women answered an early pregnancy questionnaire. We imputed 
individual early pregnancy beverage frequencies for 2,016 participants (39%). Missing 
data for preconception beverages ranged from 2% for coffee to 5% for decaf coffee. We 
used PROC MI to create 5 imputed datasets based on 46 variables in the imputation 
model. We combined beta coefficients and standard errors across the imputed datasets 
using PROC MIANAL YZE. 
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To assess departures from the proportional hazards assumption we plotted log-log 
survivor functions for each variable in categorical form. In the log-log survivor 
functions, parallel curves indicated proportional hazards. SAS statistical software 
(version 9.3, SAS Institute) was used for all analyses. 
3.3 RESULTS 
Among the 5,132 women who had a pregnancy after enrolling in the Snart Gravid 
study, a total of732 participants (14.3%) had an SAB Overall, 26% ofSABs were 
recorded only in the DNRP, 36% were reported only on a Snart Gravid follow-up 
questionnaire, 16% were documented in both sources and 22% were women who 
reported a pregnancy on a follow-up questionnaire but had no outcome information in the 
registries (Table 3.1). 
Baseline characteristics of study participants are presented in Table 3 .2. 
Preconception and early pregnancy caffeine consumption were positively associated with 
parity, education, and cigarette smoking; preconception caffeine consumption was also 
positively associated with alcohol consumption. 
Table 3.3 displays the number of SABs by strata of maternal age and caffeine 
consumption during preconception and early pregnancy. In general, the rate of SAB 
increased with maternal age but was inconsistent across categories of caffeine 
consumption. The Pearson correlation coefficient for number of cups of coffee 
consumed per day and preconception caffeine consumption was 0.96. The correlation 
between preconception caffeine consumption and caffeine intake measured during early 
pregnancy was 0.48 and the correlation between number of cups of coffee consumed per 
45 
day during early pregnancy and total caffeine consumed during early pregnancy was 
0.92. 
After adjustment for all covariates, the HRs for preconception caffeine 
consumption of 100-299, 200-299 and 2300 mg/day of caffeine compared with <100 
mg/day were 1.00 [95% CI: 0.81 , 1.24], 1.20 [95% CI: 0.96, 1.49], and 1.09 [95% CI: 
0.89, 1.34], respectively (Table 3.4). Figure 3.1 displays the relationship between 
preconception caffeine consumption and risk of SAB by gestational week using a 
restricted cubic spline. The figure indicates little association between risk of SAB and 
caffeine consumption at levels above 200 mg/day, which is consistent with the 
categorical results. Drinking three or more cups of coffee per day vs. not drinking coffee 
was also associated with an increased risk of SAB (HR: 1.22; 95% CI: 0.88, 1. 70) but 
consumption of other caffeinated beverages was not consistently associated with risk of 
SAB. The substitution model for coffee produced HRs that were nearly null (HR for 22 
cups/day 0.96 [95% CI: 0.66, 1.39]). HRs for drinking 22 servings of cola, black tea, or 
herbal/green tea per day compared with not drinking the beverages were 0.88 [95% CI: 
0.43, 1.79], 0.70 [95% CI: 0.43 , 1.14], and 0.77 [95% CI: 0.51, 1.15], respectively. 
(Table 3.5). 
The HRs for total caffeine consumption during early pregnancy for 100-199, 200-
299, and 2300 mg/day compared with <100 mg/day were 1.63 [95% CI: 1.19, 2.24], 1.49 
[95% CI: 1.04, 2.14], and 1.23 [95% CI: 0.62, 2.45], respectively (Table 3.4). The 
relationship between early pregnancy caffeine consumption and risk of SAB by 
gestational week is displayed in Figure 3.2 using a restricted cubic spline. The figure is 
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consistent with the fmdings from categorical analyses and shows that the risk of SAB 
increases to a peak around 200 mg/day followed by a decline in risk of SAB. Consuming 
less than 2 but more than 0 cups of coffee, black tea, and herbal/green tea during early 
pregnancy were associated with increased risks of SAB compared with 0 cups of the 
respective beverages but the highest categories of each beverage (2:2 cups/day) were not 
associated with an increased risk (Table 3.4). Results were inconsistent when we 
analyzed the association between each individual beverage and SAB while holding total 
caffeine constant (Table 3.5). 
The risk of SAB 2:8 weeks of gestation was higher among women who consumed 
2:300 mg/day of caffeine preconception [HR: 1.40; 95% CI: 1.00, 1.97] vs. with women 
who consumed <100 mg/day (Table 3.6). The risk oflate SAB was also higher among 
women who consumed <1-1 cups or 2:2 cups of coffee per day; HRs were 1.13 [95% CI: 
0.82, 1.56] and 1.32 [95% CI: 0.87, 2.00], respectively. The HRs for preconception 
caffeine and SAB before 8 weeks of gestation were 0.97 [95% CI: 0.73, 1.27] for 100-
199 mg/day, 1.28 [95% CI: 0.97, 1.67] for 200-299 mg/day, and 0.94 [95% CI: 0.72, 
1.22] for 2:300 mg/day. The HR for drinking 2:2 cups of herbal/green tea/day was 0.68 ; 
[95% CI: 0.39, 1.19] compared with no herbal/green tea consumption. 
Results for caffeine consumption stratified by TTP, smoking, and BMI are 
presented in Table 3. 7. The relationship between preconception caffeine and risk of SAB 
was similar among smokers and nonsmokers but the observed HRs were higher among 
women with a BMI <25 than 2:25 and among women with a TTP 2:6 months vs. <6 
months. Preconception coffee consumption also had a stronger association with SAB 
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among women with a TTP 2:6 months than among women trying for <6 months. Higher 
consumption of cola was associated with an increased risk of SAB among smokers but a 
decreased risk among non-smokers (Table 3.7). The relationships between SAB and 
black and herbal/green tea consumption were consistent across strata ofTTP, smoking, 
and BMI. Relationships between early pregnancy caffeine and caffeinated beverage 
consumption and risk of SAB were similar across strata of TTP, smoking, and BMI. 
In our cohort, a lower proportion of women who experienced nausea had an SAB 
( 10.7%) compared with women who did not experience nausea (21.1% ); the total 
prevalence of nausea in this cohort was 66%. Table 3.8 displays the hazard ratios for risk 
of SAB stratified by nausea symptoms. Overall, the risk of SAB is similar across strata 
of nausea symptoms. The mean mg/day of caffeine consumed decreased from 
preconception to early pregnancy (183 vs. 81 mg/day). After adjusting for gestational 
age at the EP questionnaire, women who experienced nausea during early pregnancy 
decreased their caffeine consumption by an average of 107 mg/day and women who did 
not report nausea decreased their caffeine consumption by 95 mg/day. The association 
between caffeine changes from preconception to early pregnancy and risk of SAB is 
presented in Table 3.9. The risks of SAB among women who changed from high to low 
caffeine consumption and among women who remained in the high consumption 
category were not elevated compared with the risk among women who remained in the 
low category; HRs 1.12 [95% CI: 0.89, 1.42] and 0.93 [95% CI: 0.49, 1.77], respectively. 
The risk of SAB among women who changed consumption from <300 mg/day before 
pregnancy to 2:300 mg/day during early pregnancy was 1.45 times higher than the risk 
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among women who consumed <300 mg/day during both preconception and early 
pregnancy (HR: 1.45; 95% CI: 0.68, 3 .09). When further adjusted for nausea, the risk 
ratio was attenuated but still elevated for these women (HR: 1.36; 95% CI: 0.64, 2.89). 
3.4 DISCUSSION 
We observed an increased risk of SAB after .2:8 weeks of gestation among women 
who consumed higher levels of caffeine consumption during the preconception period 
and for all gestational ages among women with a TTP .2:6 months. Greater coffee 
consumption during this time was also associated with an increased risk of SAB, but 
consumption of other caffeinated beverages was not associated with risk of SAB in this 
cohort. Women who consumed high amounts of caffeine during early pregnancy also 
had an increased risk of SAB, as did women who changed consumption from low to high 
during preconception to early pregnancy. However, the relationship between drinking 
individual caffeinated drinks during early pregnancy and the risk of SAB was 
inconsistent. 
Most previous studies of caffeine and risk of SAB have focused on total caffeine 
from caffeinated beverage consumption during pregnancy. Some studies have also 
included chocolate30 and caffeine from medication11'14 whereas others have primarily 
focused on coffee. 13 '21'39 In other prospective analyses from Denmark, the definition of 
high caffeine consumption has varied substantially up to .2:8 cups of coffee per dal1 and 
>900 mg/day of caffeine.40 However, several other studies used a definition of .2:300 
mg/day. 10•12•15•17•30 Most prospective studies9•10' 12•15•20'21 enrolled participants during early 
pregnancy and asked about caffeine consumption before the interview time period which 
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allows for potential exposure misclassification from recall bias and left truncation bias. 
The prospective studies that enrolled participants before pregnancy17 '30 were limited by 
small study sizes. 
Our finding that high levels of caffeine consumption during early pregnancy was 
· d · h h. h · k f SAB · · · h 10 12 1s 20 21 30 b ll 9 11 associate wit a Ig er ns o IS consistent Wit most ' ' ' ' ' ut not a , ' 
prospective studies. A prospective cohort study of 575 pregnancy planners30 
demonstrated a 2.5-fold increase in the risk ofSAB among pregnancy planners who 
consumed 300 or more mg/day of caffeine during pregnancy compared with women who 
consumed <20 mg (HR: 2.5; 95% CI: 1.0, 6.4). In a cohort of2407 women interviewed 
before 12 weeks of gestation, Savitz et ae reported little indication of an increased risk of 
SAB with caffeine or coffee consumption except among women who had an SAB before 
exposure ascertainment. A nested case-control study using prospective data from 
Denmark40 also found an increased risk of SAB among women who consumed 75-300 
mg/day of caffeine (OR: 1.26; 95% CI: 0.77, 2.06) however, in some cases the exposure 
was ascertained 2 years before the index pregnancy. Other prospective studies9•12•15•20 
that have examined relationships between caffeinated beverage consumption and SAB 
risk have reported inconsistent associations. An analysis of early pregnancy coffee 
consumption among participants in the Danish National Birth Cohort21 found that 55% of 
the cohort abstained from drinking coffee during pregnancy. They reported that the risk 
of SAB among women who drank 8 or more cups of coffee per day was 1.59 times as 
high as the risk among abstainers (HR: 1.59; 95% CI: 1.19, 2.13). 
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The present study did not collect daily readings of human chorionic gonadotropin 
(hCG), the earliest biologic marker of implantation, so it is inevitable that some early 
SABs ( <4 weeks gestation) were not identified. This limitation is common to most SAB 
studies. Missing early losses would have induced bias if caffeine consumption affected 
early losses differently than later losses. Women who were lost to follow-up or became 
pregnant a long time after completing Snart Gravid may have had a missed SAB or may 
have changed their caffeine consumption habits before the index pregnancy that we 
analyzed. The proportion of missed losses is expected to be smaller within a population 
of pregnancy planners than among the general population because pregnancy planners are 
presumably more observant of menstrual cycles. In support of this theory, 96% of the 
Snart-Gravid population that conceived during the study reported having used home 
fi h . . 41 pregnancy tests to con rrm t err pregnancies. 
A common problem with any study that uses self-reported measurements of 
caffeinated beverages is misclassification of total caffeine consumption. The caffeine 
content of various beverages can differ based on the brewing method of coffees and teas, 
the coffee beans and tea leaves themselves, and the batch of cola.42 Although we asked 
for number of servings per day of a specific volume, actual serving size and portion 
consumed are unknown. A previous study of reproductive-aged women indicated that a 
food frequency questionnaire similar to the one administered to the Snart Gravid cohort 
was effective for ranking and categorizing participants according to caffeinated beverage 
intake, but not as precise for estimating total intake in milligrams as a daily diary or 24 
hour recalls.43 Additionally, we could not account for caffeine from sources like 
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chocolate consumption, other caffeinated beverages such as energy drinks or caffeine-
containing medications, because the questionnaire did not include these items; this lack 
of information would most likely result in an underestimate of total caffeine consumed. 
Furthermore, the questionnaire did not separate green tea from herbal tea, which would 
lead to an underestimate of total caffeine intake depending on the beverage the woman 
actually consumed. 
Caffeine misclassification is unlikely to differ based on SAB status, so any 
misclassification would likely be non-differential. The non-differential misclassification 
of the exposure would likely bias estimated effects in the extreme category toward the 
null and the estimates in the middle categories of consumption in an unpredictable 
manner. Another methodolo.gic challenge relates to the fact that coffee and other 
caffeinated beverages contain myriad chemicals44'45 with unknown effects. Additionally, 
even for those consuming identical amounts of caffeine, individual variation in caffeine 
metabolism due to genetic polymorphisms in the CYP1A2 and NAT2 genes affects the 
amount of caffeine in circulation. 46 
The Snart Gravid study only collected data on caffeine intake at one point during 
pregnancy. Depending on when the woman recognized her pregnancy and the timing of 
the follow-up questionnaires (every 2 months), the information on early pregnancy 
caffeine consumption and pregnancy symptoms could be collected at different gestational 
ages for each participant. The median gestational age at completion of the EP 
questionnaire was 10 weeks. If fetal demise occurred during a pregnancy but was still 
undetected at the time of the early pregnancy questionnaire, it is possible that the 
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participant's lack of aversion to caffeine would affect her consumption habits,47 resulting 
in reverse causation. The observed changes in caffeine consumption from preconception 
to early pregnancy could be due to aversion to coffee/caffeine from pregnancy symptoms 
or due to a perceived health benefit. We did not include a question about intent or 
reasons to decrease caffeinated beverage consumption and consequently we were unable 
to separate these two reasons for change in consumption. Another prospective cohort 
study of pregnancy planners, Pregnancy Study Online (PRESTO), found that 61.9% of 
their participants decreased caffeine consumption (unpublished data). Of these, only 
12% decreased consumption due to nausea while 56% decreased consumption because 
they were worried about the effects of caffeine on the baby (personal communication). 
An issue that has affected other studies and may also be a problem in this study is 
residual confounding by smoking, especially if women are concerned about being 
stigmatized for smoking and are less likely to report their true exposure levels. The 
Internet-based methodology of the Snart Gravid study may reduce reluctance to report 
smoking, compared with face to face interviewing, but such reporting errors are unlikely 
to be completely eliminated.48 Potential residual confounding from smoking would 
inflate the observed HRs because smoking is positively associated with caffeine 
consumption and SAB. We performed a secondary analysis to determine whether 
interaction was present between caffeine consumption and smoking and did not find 
departure from additivity based on the relative excess risk due to interaction (See 
Appendix Table 3.) 
The outcome data were collected from two data sources, thereby reducing 
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potential for dependent misclassification between exposure and outcome. Nevertheless, 
because the exposure and covariates were collected using a self-administered 
questionnaire, misclassification of these variables may be correlated with each other and 
lead to residual confounding. 33 
Caffeine consumption has been shown to alter endogenous hormone levels in 
some studies2•5•7 and, in turn, these alterations in hormones could affect the risk of SAB. 
Lawson et al6 enrolled pregnant women 9 weeks after LMP and found that coffee 
consumption was inversely associated with hCG and estrone-3-glucuronide, a metabolite 
of estradiol. Other studies have reported that caffeine is inversely associated with luteal 
phase total and free estradiol5 and positively associated with luteal phase progesterone5 
and early follicular phase estradiol. 7 Kirkinen 49 and Weathersbee50 also demonstrated 
that caffeine consumption during pregnancy increases levels of catecholamines and 
cellular cyclic adenosine monophosphate that may affect blood flow to the fetus through 
vasodilation pathways. 
In summary, we found that women who consumed 2:3 cups of coffee per day 
before pregnancy had a higher risk of SAB overall. Consumption of caffeine during 
early pregnancy was also associated with a slightly higher risk of SAB. Our study was 
able to eliminate problems of left truncation bias and recall bias but the observed results 
may still be affected by reverse causation, residual confounding, especially from 
smoking, and nondifferential misclassification of exposure. 
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Table 3.1 Distribution of gestational age of SABs by identification source 
Registry Snart Gravid Both SG and 
Missing from 
Gestational registries, 
age (weeks) only follow-up only registry assumed SABb 
N=192 N=2643 N=113 N=163 
4 4 (2.1) 59 (22.4) 8 (7.1) 10 (6.1) 
5 13 (6 .8) 64 (24.2) 16 (14.2) 11 (6.8) 
6 42 (21.9) . 46 (17.4) 23 (20.4) 36 (22 .1) 
7 37(19.3) 33 (12.5) 28 (24.8) 40 (24.5) 
8 20 (10.4) 22 (8.3) 18 (15.9) 36 (22.1) 
9 10 (5.2) 13 (4.9) 7 (6.2) 21 (12.9) 
10 17 (8.9) 8 (3.0) 7 (6.2) 6 (3 .7) 
11 23 (12.0) 8 (3 .0) 4 (3.5) 3 (1 .8) 
12 12 (6.3) 7 (2.7) 2 (1.8) 
13 3 (1.6) 1 (0.4) 
14 2 (1.0) 3 (1.1) 
15 
16 2 (1.0) 
17 1 (0.5) 
18 4 (2.1) 
19 1 (0.5) 
20 
21 1 (0.5) 
aThe SG follow-up questionnaires are less likely to identify later losses (>8 weeks of gestation) because they are conducted every two 
months 
bGestational age for participants who were completely missing from the registry were multiply imputed, frequencies presented are from 
the first imputation dataset. 
Table 3.2 Age-adjusted distribution of characteristicsa of 5132 women according to daily preconception and early pregnancy 
consumption of caffeine from the first imputed dataset 
Preconception caffeine consumption (mg/day) I Early pregnancy caffeine consumption (mg/day) 
<100 100-199 200-299 ::>:300 <100 100-199 200-200 ::>:300 
Parity(%) 
Nulliparous 67 .9 66.7 69.8 63 .5 67 .8 67.7 66.5 59.3 
1 Birth 24.9 24.9 22.7 27. 1 24.6 24.6 24.5 29.4 
> 1 births 7.3 8.5 7.5 9.6 7.6 7.8 9.0 11.3 
Vocational training/education(%) 
No vocational training 12.2 12.2 11.1 12.3 11.7 9.8 13 .8 17.6 
Semi-skilled/basic training 16.7 16.7 14.1 13 .9 16.5 15.6 14.4 11.8 
Higher education (S4 years) 53.0 50.3 47.4 47.3 51.3 49.5 49.3 47.0 
Higher education (>4 years) 18.1 20.8 27.4 26.4 20.6 25 .1 22.6 23 .6 
Smoking Status(%) 
Non-smokers 85 .3 79.4 80.2 66.8 
I 
88.8 88 .1 74.8 70.3 
<10 cigarettes/day 8.5 10.5 11.5 16.8 11.2 11.9 25.2 29.7 
10 or more cigs/day 6.2 10.1 8.4 16.4 
Vl Body Mass Index (kg/m2)(%) 0\ 
<20 15 .2 14.2 14.9 14.8 14.5 15.4 16.6 14.7 
20-24.9 50.0 52.7 58.0 54.1 52.3 53 .6 51.0 54.9 
25-29.9 20.8 20.5 20.3 20.4 20.6 20.1 20.6 18.4 
::>:30 14.1 12.7 6.8 10.6 12.6 10.9 11.8 12.0 
Alcohol categories(%) 
0 drinks per week 42.6 32.3 27.3 21.2 99.9 100 99.5 98 .7 
1drink/wk 16.2 14.6 15.6 11.9 0.1 0 0.5 1.3 
2 drinks/wk 14.7 13.7 15.5 16.2 0 0 0 0 
3-6 drinks/wk 20.8 29.5 30.4 34.9 0 0 0 0 
::>:7 drinks/wk 5.8 10.0 11.1 15.8 0 0 0 0 
METs Categories(%) 
<lOMETs 16.6 15.3 15.2 14.5 16.0 14.3 15 .0 17.7 
10-19 METs 32.8 32.9 29.1 32.7 33.4 31.1 27.9 31.9 
20-39 METs 34.2 34.9 36.9 37.2 33.7 37.9 40.1 35 .1 
::>:40METs 16.4 16.8 18.9 15.6 16.9 16.7 17.1 15.4 
Time to re nanc 57.5 57.0 53 .9 54.2 55.4 56.0 61.1 52.2 
• Characteristics are presented as percentages within levels of caffeine consumption based on the first imputation dataset, and are standardized to the age 
distribution of the cohort at baseline. 
VI 
-...) 
Table 3.3 Numb era of spontaneous abortions and gestational weeks at risk by age and preconception caffeine consumption 
Dai ly preconception caffeine consumption (mg) Dai ly early pregnancy caffeine consumption (mg) 
Age (Years) <100 100-199 200-299 >300 <100 100-199 200-299 >300 Total 
::;20 
SAB 15 3 0 1 16 2 1 0 19 
Gestational weeks 1917 305 0 216 1979 130 329 0 2438 
Rate/1000 GW 7.8 9.8 0 4.6 8.1 15.4 3.0 0 7.8 
21-24 
SAB 62 15 6 11 64 . 7 18 5 94 
Gestational weeks 10182 2617 1116 1396 12024 1138 1684 465 1531 1 
Rate/1000 GW 6.1 5.7 5.4 7.9 5.3 6.2 10.7 10.8 6.1 
25-28 
SAB 120 45 38 42 132 26 66 21 245 
Gestational weeks 18482 6334 4935 6480 25164 3432 5141 2494 36231 
Rate/1000 GW 6.5 7. 1 7.7 6.5 5.2 7.6 12.8 8.4 6.8 
29-32 
SAB 84 37 44 54 124 25 42 28 219 
Gestational weeks 12434 5373 4724 7646 18787 3412 5122 2856 30177 
Rate/1000 GW 6.8 6.9 9.3 7.1 6.6 7.3 8.2 9.8 7.3 
33-36 
SAB 36 18 20 46 45 27 30 18 120 
Gestational weeks 4569 2250 2129 3792 6723 1765 2460 1792 12740 
Rate/1000 GW 7.9 8.0 9.4 12.1 6.7 15.3 12.2 10.0 9.4 
?.37 
SAB 10 4 4 17 11 6 7 11 35 
Gestational weeks 916 605 594 1289 1533 540 639 692 3404 
Rate/1000 GW 10.9 6.6 6.7 13.2 7.2 11.1 11.0 15.9 10.3 
Age-standardized rate 6.9 7.0 7.8 7.8 6.0 8.6 10.7 9.5 
Age-standardized rate difference [ret] 0.1 1.0 0.9 [ret] 2.6 4.8 3.5 
95% CI -1.3, 1.6 -0.7, 2.6 -0.6, 2.4 0.7, 4.5 3.0, 6.5 1.1, 5.9 
Standardized rate ratio [ret] 1.02 1.14 1.13 [ret] 1.43 1.79 1.58 
95% CI 0.83, 1.26 0.91 , 1.42 0.93, 1.38 1.14, 1.81 1.49, 2.16 1.21, 2.06 
aFrom the first imputation dataset 
Table 3.4 Hazard ratios for the association of SAB with consumption of caffeine and caffeinated beverages 
Early pregnancy consumption 
N Total Crude N Total Crude Adjustedb HR SABa owa SAB" owa 95%CI 
Caffeine (mg/day) 
<100 327 48500 1.00 [Reference] 392 6621 0 1.00 [Reference] 
100-199 122 17484 1.04 1.00 [0.81, 1.24] 93 10417 1.67 1.63 [1. 19, 2.24] 
200-299 112 13498 1.24 1.20 [0.96, 1.49] 164 15375 1.66 1.49 [1.04, 2.14] 
~300 171 20819 1.22 1.09 [0.89, 1.34] 83 8299 1.46 1.23 [0.62, 2.45] 
Coffee (cups/ day)" 
0 295 43254 1.00 [Reference] 488 77622 1.00 [Reference] 
<1-1 325 44039 1.08 1.02 [0.86, 1.20] 220 18706 1.54 1.39 [0.88, 2.18] 
2 67 8580 1.15 1.02 [0.77, 1.35] 24 3973 0.80 0.65 [0.28, 1.51] 
~3 45 4428 1.46 1.22 [0.88, 1. 70] 
Cola (servings/day)" 
Vo 0 276 36236 1.00 [Reference] 661 91867 1.00 [Reference] 00 
<1-1 448 62995 0.95 0.94 [0.81, 1.11] 68 7859 1.11 1.02 [0.67' 1.55] 
~2 8 1070 1.01 0.93 [0.45, 1.88] 3 575 0.74 0.72 [0.18, 2.84] 
Black tea 
(cups/ day)" 
0 403 55446 1.00 [Reference] 574 84549 1.00 [Reference] 
<1-1 312 41618 1.05 1.06 (0.91, 1.24] 152 14327 1.54 1.51 [1.19, 1.93] 
~2 17 3237 0.77 0.73 [0.45, 1.20] 6 1425 0.90 0.87 [0.38, 2.02] 
Herbal/Green tea 
(cups/day)" 
0 461 62180 1.00 [Reference] 566 81932 
<1-1 245 33676 0.97 0.98 [0.84, 1.16] 157 15977 
>2 26 4445 0.81 0. 78 0.52, 1.16 9 2392 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted for maternal age, physical activity, parity, vocational training/education, smoking, and prior spontaneous abmiion. The 
preconception model also includes alcohol consumption. 
cEstimates for coffee, cola, black tea, and green/herbal tea are mutually adjusted for each other. 
Table 3.5 Hazard ratios for the association of SAB with individual caffeinated beverages using substitution models. 
Preconception I Early pregnancy 
N Total Adjusted0 HR N Total Adjustedb HR 
SABa aw• [95%CI] SAB" GW" [95%CI] 
Coffee 
(cups/day)" 
0 295 43254 1.00 [Reference] 488 77622 1.00 [Reference] 
<1-1 325 44039 1.01 [0.85, 1.20] 220 18706 1.25 [0.65, 2.38] 
2:2 112 13008 0.96 [0.66, 1.39] 24 3973 0.46 [0.12, 1.78] 
Cola 
(servings/day)" 
0 276 36236 1.00 [Reference] 661 91867 1.00 [Reference] 
Vl < 1-1 448 62995 0.94 [0.80, 1.1 OJ 68 7859 1.00 [0.64, 1.55] 
\0 2:2 8 1070 0.88 [0.43, 1.79] 3 575 0.64 [0.15 , 2.67] 
Black tea 
(cups/day)" 
0 403 55446 1.00 [Reference] 574 84549 1.00 [Reference] 
<1-1 312 41618 1.08 [0.93, 1.25] 152 14327 1.58 [1.18, 2.12] 
2:2 17 3237 0.70 [0.43 , 1.14] 6 1425 0.81 [0.29, 2.25] 
Herbal/Green tea 
(cups/day)" 
0 461 62180 1.00 [Reference] 566 81932 
<1-1 245 33676 1.02 [0.87, 1.20] 157 15977 
>2 26 4445 0.77 0.51, 1.15 9 2392 
"Frequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted for maternal age, physical activity, parity, vocational training/education, smoking, and prior spontaneous abortion. The 
preconception model also includes alcohol consumption. 
cEstimates for coffee, cola, black tea, and herbal/green tea are from substitution models that include continuous caffeine consumption as a 
covariate. 
Table 3.6 Hazard ratios for the association of caffeine and caffeinated beverage consumption before pregnancy with early ( <8 
weeks) and late SAB 
Late SAB ~8 weeks 
N Total Crude N Total Crude Adjustedb HR SAB" GW" SAB" GW" [95%CI] 
Caffeine (mg/day) 
<100 216 1401 1.00 [Reference] 111 47099 1.00 [Reference] 
100-199 80 521 0.99 0.97 [0.73 , 1.27] 42 16963 1.14 1.07 [0.73 , 1.58] 
200-299 77 491 1.28 1.28 [0. 97' 1.67] 35 13007 1.15 1.05 [0.69, 1.59] 
~300 97 621 1.02 0.94 [0.72, 1.22] 74 20198 1.65 1.40 [1.00, 1.97] 
Coffee (cups/dayt 
0 204 1284 1.00 [Reference] 91 41970 1.00 [Reference] 
<1 -1 199 1324 1.00 0.96 [0.76, 1.22] 126 42715 1.25 1.13 [0.82, 1.56] 
~2 67 426 1.09 0.98 [0.71, 1.35] 45 12582 1.61 1.32 [0.87, 2.00] 
Cola (servings/dayt 
0 168 1059 1.00 [Reference] 108 35177 1.00 [Reference] 
0\ <1-1 296 1933 0.99 0.99 [0.80, 1.22] 152 61062 0.90 0.88 [0.64, 1.19] 
0 ~2 6 42 1.07 1.00 [0.41' 2.45] 2 1028 0.89 0.79 [0.19, 3.35] 
Black Tea (cups/dayt 
0 255 1678 1.00 [Reference] 148 53768 1.00 [Reference] 
<1-1 203 1274 1.08 1.11 [0.91, 1.35] 109 40344 0.99 0.99 [0.76, 1.29] 
~2 12 82 0.83 0.80 [0.44, 1.46] 5 3155 0.66 0.61 [0.24, 1.51 ] 
Herbal/Green tea 
(cups/dayt 
0 305 1990 1.00 [Reference] 156 60190 1.00 [Reference] 
<1-1 151 949 0.93 0.96 [0.78, 1.18] 94 32727 1.03 1.02 [0.77, 1.35] 
>2 14 95 0.69 0.68 [0.39, 1.19 12 4350 1.00 0.92 [0.48 , 1.79 
"Frequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted for maternal age, physical activity, parity, vocational training/education, alcohol consumption, smoking, and prior spontaneous 
abortion. 
cEstimates for coffee, cola, black tea, and herbal/green tea are mutually adjusted for each other. 
Table 3.7. Hazard ratios for the association b etween caffeine consumption and SAB stratified by time to pregn ancy, smoking 
status, and bod mass index. 
Preconception Early Pregnancy 
SAB/Total TTP <6 monthsb SAB/Total TTP ~6 monthsb SAB/Total TTP <6 monthsb SAB/Total TTP ~6 monthsb aw• aw• aw• aw· 
Caffeine 
(mg/day) 
<100 147/20690 1.00 [Reference] 180/27810 1.00 [Reference] 162/29980 1.00 [Reference] 230/36230 1.00 [Reference] 
100-199 39/7769 0. 73 [0.51 ' 1.05] 83/9715 1.24 [0.95, 1.61] 41 /4569 1.84 [1.24, 2.72] 52/5848 1.46 [0.92, 2.32] 
200-299 54/6109 1.24 [0.89' 1.71] 58/7389 1.14 [0.84, 1.55] 75/5895 1.70 [1.03, 2.80] 89/9480 1.35 [0.91, 1.99] 
~300 76/9827 1.01 [0.74, 1.37] 95/10992 1.15 [0.88, 1.50] 38/3951 1.09 [0.34, 3.53] 45/4348 1.30 [0.76, 2.21 ] 
Coffee 
(cups/day)" 
0 130/18525 1.00 [Reference] 165/24729 1.00 [Reference] 203/35231 1.00 [Reference] 285/42391 1.00 [Reference] 
<1-1 138/19714 0.96 [0.74, 1.24] 187/24325 1.06 [0.85 , 1.32] 101/7182 1.55 [0.80, 3.01 ] 119/11524 1.27 [0.86, 1.89] 
~2 48/6156 0.94 [0.65, 1.35] 64/6852 1.20 [0.88, 1.64] 12/1982 0.59 [0.17, 2.03] 1211991 0.66 [0.29, 1.52] 
Cola 
0'1 
(servings/day)0 
........ 0 122/16020 1. 00 [Reference] 154/20216 1.00 [Reference] 285/40647 1.00 [Reference] 376/51220 1.00 [Reference] 
<1-1 190/27924 0.89 [0.70, 1.14] 258/35071 0.98 [0.79, 1.21 ] 30/3480 0.89 [0.34, 2.30] 38/4379 1.09 [0.77, 1.54] 
~2 4/451 1.01 [0.37, 2.78] 4/619 0.82 [0.30, 2.24] 1/268 - 2/307 1.06 [0.26, 4.4 1] 
Black Tea 
( cups/day)0 
0 177/22843 1.00 [Reference] 226/32603 1.00 [Reference] 247/37214 1.00 [Reference] 327/47335 1.00 [Reference] 
<1-1 133119918 0.85 [0.67, 1.07] 179/21700 1.25 [1.02, 1.53] 69/6257 1.55 [1.14, 2.1 1] 83/8070 1.45 [1.03, 2.04] 
~2 6/1634 0.45 [0.20, 1.03] 11/1603 1.07 [0.58, 1.97] 0/924 - 6/501 1.93 [0. 78. 4.80] 
Herbal/Green 
tea (cups/day)0 
0 185/26396 1.00 [Reference] 276/35784 1.00 [Reference] 242/36566 1.00 [Reference] 324/45366 1.00 [Reference] 
<1-1 118/15912 1.04 [0.82, 1.34] 127117764 0.95 [0.76, 1.18] 72/6568 1.48 [0.95, 2.32] 85/9409 1.15 [0.77. 1.72] 
~2 13/2087 0.88 [0.49, 1.57] 13/2358 0.68 [0.39, 1.21] 2/1261 0.42 [0.09, 2.04] 711131 0.79 [0.31. 1.99] 
aFrequencies and gestational weeks (GW) from the first imputation dataset. 
b Adjusted models include maternal age, physical activity, parity, vocational training/education, smoking, and prior spontaneous abortion. 
The preconception model also includes alcohol consumption. 
0Estimates for coffee, cola, black tea, and herbal/green tea are mutually adjusted for each other. 
Table 3.7 continued. Hazard ratios of the association between caffeine consumption and SAB stratified by time to pregnancy, 
smoking status, and bod mass index. 
Preconception Early Pregnancy 
SAB/Total Nonsmokerb SAB/Total Smokerb SAB/Total Nonsmokerb SAB/Total Smokerb ow• ow• ow• ow• 
Caffeine 
(mg/day) 
<100 275/41107 1.00 [Reference] 5217393 1.00 [Reference] 320/55686 1.00 [Reference] 72110524 1.00 [Reference] 
100-1 99 96/14033 1.01 [0.79, 1.28] 26/3451 1.06 [0.65, 1.71] 77/8992 1.65 [1.20, 2.27] 16/1425 1.51 [0.70, 3.26] 
200-299 83/11235 1.08 [0.84, 1.40] 29/2263 1.78 [1.1 0, 2.88] 121110793 1.59 [1.00, 2.53] 43/4582 1.27 [0.76, 2.14] 
2:300 116114522 1.12 [0.88, 1.41] 55/6297 1.17 [0.78, 1.76] 52/5426 1.31 [0.64, 2.67] 31 /2873 1.12 [0.50, 2.51] 
Coffee 
(cups/day/ 
.0 244/37178 1.00 [Reference] 51/6076 1.00 [Reference] 398/65520 1.00 [Reference] 90/12102 1.00 [Reference] 
<1-1 256/35091 1.06 [0.88, 1.28] 69/8948 0.89 [0.61, 1.30] 157113112 1.46 [0.87, 2.46] 63/5594 1.21 [0.73 , 2.01 ] 
2:2 70/8628 1.1 1 [0.84, 1.48] 42/4380 1.04 [0.67, 1.62] 15/2265 0.74 [0.28, 1.95] 911708 0.56 [0.20, 1.60] 
Cola 
0\ 
(servings/day/ 
N 0 233/30459 1.00 [Reference] 43/5777 1.00 [Reference] 525174813 1.00 [Reference] 136/1 7054 1.00 [Reference] 
<1-1 333/49568 0.90 [0.75 , 1.08] 115/13427 1.13 [0.79, 1.63] 43/5591 1.06 [0.64, 1.76] 25/2268 0.97 [0.50, 1.89] 
2:2 4/870 0.61 [0.23, 1.66] 4/200 2.14 [0.75, 6.13] 2/493 0.41 [0.06, 3 .08] 1/82 1.29 [0.16, 10.48] 
Black Tea 
( cups/day)0 
0 306/43274 1.00 [Reference] 97/12172 1.00 [Reference] 451/68036 1. 00 [Reference] 123/16513 1.00 [Reference] 
<1-1 250/34911 1.02 [0.86, 1.21 ] 62/6707 1.19 [0.85, 1.65] 115/1 1733 1.48 [1.10, 2.01 ] 37/2594 1.60 [1.00, 2.55] 
2:2 14/2712 0.74 [0.43, 1.27] 3/525 0.63 [0.20, 2.02] 4/1128 0.75 [0.28, 1.96] 2/297 1.17 [0.30, 4.56] 
Herbal/Green 
tea (cups/day/ 
0 341/47900 1.00 [Reference] 120/14280 1.00 [Reference] 433/65515 1.00 [Reference] 133/1 6417 1.00 [Reference] 
<1-1 208/29 168 0.97 [0.81, 1.16] 37/4508 1.04 [0. 71' 1.54] 129/ 13331 1.30 [0.94, 1.8 1] 28/2646 1.10 [0.4 7, 2.59] 
2:2 21 /3829 0.72 [0.46, 1.14] 5/616 0.90 [0.36, 2.28] 8/2051 0.62 [0.25, 1.56] 1/341 0.58 [0.07, 4.65] 
•Frequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted models include maternal age, physical activity, parity, vocational training/education, smoking, and prior spontaneous abortion. 
The preconception model also includes alcohol consumption. 
cEstimates for coffee, cola, black tea, and herbal/green tea are mutually adjusted for each other. 
Table 3.7 continued. Hazard ratios for the association between caffeine consumption and SAB, stratified by body mass index. 
SAB/Total BMI <25b SAB/Total BMI 2':25b SAB/Total BMI <25b SAB/Total BMI 2':25b ow• ow• GW" ow• 
Caffeine 
(mg/day) 
<100 208/31800 1.00 [Reference] 119/16700 1.00 [Reference] 258/44510 1.00 [Reference] 134/21700 1.00 [Reference] 
I 00-199 82111688 1.06 [0.82, 1.38] 40/5796 0.9 1 [0.63, 1.32] 62/7281 1.56 [1.10, 2.19] 31/3136 1.78 [1.02, 3.13] 
200-299 85/9909 1.26 [0.97, 1.64] 27/3589 1.03 [0.67, 1.58] 112/10343 1.54 [1.07, 2.22] 52/5029 1.36 [0.78, 2.37] 
2':300 118/14601 1.15 [0.90, 1.47] 53/6218 1.00 [0. 70, 1.41] 61 /5861 1.27 [0.59, 2. 75] 22/2438 . 1.07 [0.50, 2.30] 
Coffee 
(cups/day)" 
0 176/27794 1.00 [Reference] 119/15460 1.00 [Reference] 321/52327 1.00 [Reference] 167/25295 1.00 [Reference] 
<1-1 247/30921 1.23 [1.00, 1.52] 78/13118 0.68 [0.50, 0.92] 155/12901 1.46 [0.90, 2.38] 65/5805 1.21 [0.68, 2.17] 
2':2 70/9283 1.09 [0.80, 1.46] 42/3725 1.15 [0.78, 1.68] 17/2770 0.67 [0.28, 1.59] 7/1203 0.56 [0.16, 1.97] 
Cola 
(servings/day)" 
0 204/27925 1.00 [Reference] 72/8311 1.00 [Reference] 459/63846 1.00 [Reference] 202/2802 1 1.00 [Reference] 
< 1-1 285/39503 1.05 [0.87, 1.26] 163/23492 0.80 [0.60, 1.07] 33/4015 1.03 [0.59, I. 78] 35/3844 1.01 [0.57, 1.77] 
0'\ 2':2 4/570 0.92 [0.34, 2.51] 4/500 0.89 [0.32, 2.46] 1/137 1.33 [0.18, 9.53] 2/438 0.47 [0.06, 3.81] w 
Black Tea 
(cups/day)" 
0 265/35918 1.00 [Reference] 138/19528 1.00 [Reference] 382/56809 1.00 [Reference] 192/27740 1.00 [Reference] 
<1-1 215/29676 1.00 [0.83, 1.21] 97/11942 1.2 1 [0.93, 1.59] 108/10286 1.46 [1.14, 1.86] 44/4041 1.63 [1 .05, 2.54] 
2':2 13/2404 0.75 [0.42, 1.32] 4/833 0.68 [0.25, 1.85] 3/903 0.74 [0.22, 2.53] 3/522 1.09 [0.35, 3.40] 
Herbal/Green 
tea (cups/day)c 
0 295/39373 1.00 [Reference] 166/22807 1.00 [Reference] 372/53715 1.00 [Reference] 194/28217 1.00 [Reference] 
<1-1 180/25026 0.94 [0.77, 1.14] 65/8650 1.07 [0.79, 1.44] 113/12329 1.23 [0.91' 1.66] 44/3648 1.42 [0.66, 3 .08] 
2':2 18/3599 0.66 [0.40, 1.07] 8/846 1.23 [0.60, 2.54] 8/1954 0.63 [0.27' 1.49] 1/438 
•Frequencies and gestational weeks (GW) from the first imputation dataset 
b Adjusted models include maternal age, physical activity, parity, vocational training/education, smoking, and prior spontaneous abortion. The 
preconception model also includes alcohol consumption. 
cEstimates for coffee, cola, black tea, and herbal/green tea are mutually adjusted for each other. 
Table 3 .8. Hazard ratios for the association of SAB with caffeine and caffeinated beverage consumption during early 
pregnancy stratified by nausea symptoms during early pregnancy 
N Total GWa Nauseab I S~a Total GWa No Nauseab SABa 
Caffeine (mg/day) 
<100 210 47301 1 . 00 [Reference] 182 18909 1.00 [Reference] 
100-199 50 7067 1.67 [1.19, 2.35] 43 3350 1.45 [0.90, 2.34] 
200-299 72 8936 1.34 [0.83 , 2.16] 92 6439 1.31 [0.89, 1.94] 
~300 31 4608 1.19 [0.52, 2.71 ] 52 3691 1.00 [0.51 ' 1.95] 
Coffee (cups/day)" 
0 262 55006 1.00 [Reference] 226 22616 1.00 [Reference] 
<1-1 96 10840 ·1.24 [0.74, 2.07] 124 7866 1.27 [0.76, 2.11] 
~2 5 2066 
Coia (servings/day)" 
0.45 [0.06, 3.08] 19 1907 0.60 [0.29, 1.23] 
0\ 0 321 62566 1.00 [Reference] 340 29301 1.00 [Reference] ~ 
<1-1 40 4952 1. 16 [0.63, 2.1 1] 28 2907 0.80 [0.48, 1.34] 
~2 2 394 0.82 [0.13, 5.37] 1 181 0.54 [0.08, 3.84] 
Black Tea (cups/day)" 
0 286 57793 1.00 [Reference] 288 26756 1.00 [Reference] 
<1-1 74 9305 1.54 [1.11 , 2.15] 78 5022 1.41 [1.08, 1.85] 
~2 3 814 1.11 [0.30, 4.08] 3 611 0.57 [0.19, 1.72] 
Herbal/Green tea (cups/day)" 
0 284 55815 1.00 [Reference] 282 26117 
<1-1 76 10688 1.36 [0.86, 2.15] 81 5289 
>2 3 1409 0.49 0.12, 1.93] 6 983 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
b Adjusted models include maternal age, physical activity, parity, vocational training/education, smoking, and prior spontaneous abmiion. 
The preconception model also includes alcohol consumption. 
cEstimates for coffee, cola, black tea, and herbal/green tea are mutually adjusted for each other. 
0'\ 
Vl 
Table 3.9. Changes in caffeine consumption from preconception to early pregnancy and risk ofSAB. 
consumption 
NSABa Total GWa Change in caffeine Crude Adjustedb HR [95% CI] Adjustedb with Nausea HR [95% CI] 
<300 mg/day-<300 mg/day 525 76702 1.00 [Reference] 
<300 mg/day-~300 mg/day 36 2780 1.61 1.45 [0.68, 3.09] 
~300 mg/day-<300 mg/day 124 15300 1.23 1.12 [0.89, 1.42] 
>300 mg/day-~300 mg/day 47 5519 1.08 0.93 [0.49, 1.77] 
aFrequencies and gestational weeks (GW) from the first imputation dataset . 
1.36 [0.64, 2.89] 
1.12 [0.88, 1.42] 
0.84 [0.45, 1.57] 
b Adjusted models include maternal age, physical activity, parity, vocational training/education, smoking, and prior spontaneous abortion. 
Figure 3 .1. Relationship between most recent caffeine consumption and risk of SAB 
among all women in the SG cohort fitted by a restricted cubic spline. 
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Figure 3.2. Relationship between early pregnancy caffeine consumption and risk of SAB 
fitted by a restricted cubic spline. 
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4 HISTORY OF ORAL CONTRACEPTIVE USE AND RISK OF SPONTANEOUS 
ABORTION 
4.1 INTRODUCTION 
Pregravid oral contraceptive (OC) use is a common exposure that has been 
associated with a decreased risk of SAB in some1-6 but not all studies.7-9 Several 
investigators have hypothesized that the observed reductions in SAB incidence are due to 
OCs maintaining the reserve of healthy oocytes available for reproduction, but this 
hypothesis has not been confirmed by laboratory investigations. 10•11 In addition, OCs can 
alter the endogenous hormonal milieu, even after discontinuation, 12 though recent use of 
OCs may be a marker for higher fertility, and the results of studies measuring hormone 
concentrations in OC users have been inconclusive. 13•14 Little is known about the 
influence of dose of estrogen or type of progestin on SAB risk, particularly the newest 
OCs that contain fourth generation progestins. Although the exact mechanisms of action 
that might link OCs to SAB are unclear at this point, the high prevalence of OC use15•16 
makes it important to determine whether a relationship truly exists. 
We examined SAB risk in relation to self-reported history of OC use, measured 
by duration and recency of OC use, and dose of estrogen and generation of progestin in 
the most recent OC used by women enrolled in a prospective cohort study of women 
planning a pregnancy in Denmark. 
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4.2METHODS 
4.2.1 Data collection 
The Snart-Gravid study is an Internet-based prospective cohort study of time to 
pregnancy. Recruitment began in 2007 when an advertisement was placed on a Danish 
health-related website (www.netdoktor.dk) and a coordinated media strategy was 
launcbed.17-19 Enrollment and primary data collection were conducted via a self-
administered questionnaire on the study website (www.snart-gravid.dk). Contact with 
participants was maintained through the study website and e-mail. 
Before enrollment, participants completed a consent form and an online screening 
questionnaire to verify eligibility. Women eligible to participate in Snart Gravid were 
aged 18-40 years, residents of Denmark, in a stable relationship with a male partner, not 
using fertility treatment, and trying to become pregnant. Participants were required to 
provide a valid e-mail address and their Civil Personal Registration (CPR) number, a 
unique 1 0-digit personal identification number assigned to each Danish resident. After 
38 months of recruitment, 5,921 women bad enrolled in the study. The study was 
approved by the Danish Data Protection Board and the Institutional Review Board of 
Boston University Medical Campus. 
The baseline questionnaire collected information on demographics, lifestyle and 
behavioral factors, and reproductive and medical history. Initially, women were 
randomized with equal probability to receive either a short- or long-form version of the 
baseline questionnaire. Because completion rates and missing data were similar for both 
questionnaires, 19 after six months all new participants received the long-form baseline 
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questionnaire. Participants were contacted every two months by e-mail with a reminder 
to fill out a follow-up questionnaire. Follow-up questionnaires assessed changes in 
exposures and pregnancy status, including whether any clinically-recognized pregnancy 
losses had occurred. Follow-up continued until conception occurred or for a maximum of 
12 months. 
To obtain information on pregnancy outcomes among women in the cohort, we 
linked each woman's CPR number to the Danish National Registry of Patients (DNRP) 
and Danish Medical Birth Registry (DMBR). The DNRP provides information on 
hospital and outpatient encounters (including SAB and therapeutic abortion (TAB)) and 
the DMBR gives information on all live and still births after 22 gestational weeks 
(GWs).20'21 Pregnancy outcomes occurring after the baseline enrollment date in the Snart 
Gravid cohort were identified using ICD-10 codes (D003 for SAB and D004 for TAB) 
in the DNRP. A validation study ofDNRP data found that 30% of self-reported SABs 
were not registered in the DNRP;20 however, this study examined records from 1991-
1995, before the registry started to include data from outpatient clinics (2:1995). Another 
study that compared the DNRP with data from individual medical records found a 
positive predictive value of98.7%.21 
4.2.2 Assessment ofOC history 
Exposure to OCs (duration and recency of use, dose of ethinyl estradiol and type 
of progestin) was ascertained via self-report on the baseline Snart Gravid questionnaire. 
Participants were asked to report the brand name, age at first use, and duration of use for 
each type of contraceptive pill that they had ever used; up to a total of 6 brands. To 
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enhance recall, the questionnaire included a list of all OC brand names available in 
Denmark. Women who used OCs as their last method of birth control were also asked if 
they had intentionally delayed their conception attempt and if so, for how many cycles. 
Some clinicians may suggest delaying pregnancy attempts because OCs have been 
associated with transient delay in return of fertility. 22'23 Total duration of OC use was 
calculated by summing the duration of each pill that the woman used. The categories of 
duration were chosen based on the overall distribution of the variable. We defined 
recency of OC use as the number of months between the last use of OCs and the date of 
conception (date of event-gestational age in days). Among women who used OCs as 
their most recent method of birth control, we calculated recency in months using the 
following formula: ((date ofLMP- date of the baseline questionnaire) + (months trying 
to get pregnant before baseline *30)/30). For women who delayed their pregnancy 
attempt, we added the number of months of waiting time to the formula above. We 
calculated recency among women who had used the pill in the past, but not as their most 
recent method of birth control by subtracting the approximate age of last use of OCs 
(using the age started and duration ofuse of the most recent brand ofOCs) from the age 
at LMP and multiplying by 12. Dose of estrogen and type of progestin were only 
analyzed for the last reported pill. We classified the most recent brand of OCs by the 
amount of estrogen it contained: none (progestin-only pill), low-dose ( <30 micrograms), 
and high-dose (2:30 micrograms), and also by 'generation' defmed by progestin content: 
first generation (norethindrone), second generation (norgestrel and levonorgestrel), third 
generation ( desogestrel and gestodene ), and fourth generation ( drospirenone ). 24 We 
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combined first and second generation pills into one category because very few women 
(n=63) had used first generation OCs as their most recent brand. Subanalyses excluding 
women who had used a 1st generation progestin produced similar results (results not 
shown). See Appendix Table 4 for the frequencies of individual brands. 
4. 2. 3 Assessment of spontaneous abortion 
Women who experienced a pregnancy loss were asked to report the date of the 
loss and gestational weeks at loss (time since the last menstrual period). The DNRP 
provided information on occurrences ofSAB up to 22 gestational weeks and any TAB, 
the dates of these events, and the gestational age at which the pregnancy ended. For 
pregnancy losses recorded in both the registry and on a questionnaire, we used data from 
the DNRP (based on either early ultrasound fetometry or LMP) to measure gestational 
week of pregnancy loss. In Denmark, the first pregnancy-related ultrasound is around 12 
weeks of gestation so gestational ages of SABs after this time are likely based on 
ultrasound. For SABs reported only on a Snart Gravid follow-up questionnaire, 
gestational age was calculated as the number of weeks from the last menstrual period to 
the date of pregnancy loss, rounded to the nearest whole week. The mean reported 
gestational age from SG was slightly lower 6.8 vs. 7.2 weeks in the registry. 
There were 158 women who reported a pregnancy on a Snart Gravid follow-up 
questionnaire but did not have any data from that pregnancy recorded in either the 
hospital or birth registries. For this analysis, we assumed that these women had an early 
SAB. We used multiple imputation to impute a gestational age :S12 weeks for each of 
these presumed SABs. Sensitivity analyses in which we excluded these pregnancies 
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produced similar results (Appendix Table 5). 
4.2.4 Assessment of confounders 
Data on maternal age, smoking status, alcohol and caffeine consumption, physical 
activity, parity, height and weight, and vocational training/education were self-reported 
on the baseline questionnaire. We estimated total metabolic equivalents (METs) per 
week by summing the METs from moderate physical activity (hours per week multiplied 
by 3.5 METs) and vigorous exercise (hours per week multiplied by 7.0 METs)? 5 Body 
mass index was calculated as kg/m2 and was categorized based on the WHO standards. 
Smoking status and consumption of alcohol and caffeine were updated on the baseline 
questionnaire and on all subsequent follow-up questionnaires. 
4.2.5 Study population 
The present analysis was restricted to women who conceived a clinically-
recognized pregnancy after emolhnent in the cohort. The analyses were restricted to the 
first pregnancy after emollment in Snart Gravid because we could not determine whether 
a woman took OCs between pregnancies. We excluded 126 women because they were 
not living in Denmark during follow-up, 10 women because they did not provide a valid 
CPR, and 653 (11 %) women who did not conceive during the follow-up period (as 
indicated by the absence of pregnancy data on the follow-up questionnaires, the DNRP, 
and the DMBR) (See Figure 2.1). We also excluded 58 women who most recently used 
other hormonal contraception (vaginal ring, hormone-containing IUD), 45 women who 
reported using more than 6 brands of OCs and 167 women who were never users of OCs. 
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4.2. 6 Data analysis 
We assessed SAB risk in relation to recency and duration of OC use and dose and 
generation of the most recent pill using a time-to-event analysis. Time to SAB was 
measured in gestational weeks. We divided recency of OC use into the following 
categories: 0-1, 2-6, 7-12, and> 12 months. The categories of duration were: <4, 4-7, 8-
11, and 12 or more years. We examined the shape and magnitude of the relation between 
recency and duration of OC use and SAB risk by using restricted cubic splines.26 
We used Cox proportional hazards regression models, with gestational weeks as 
the time scale, to estimate hazard ratios (HRs) and 95% confidence intervals (Cis) for OC 
history variables associated with SAB. We assumed that there was a true but unknown 
ordering for tied event times and used the "exact" option in SAS PROC PHREG27 which 
takes into account all possible orderings of event times. Thus, the HR is approximately 
equal to the average per-week risk of SAB for the exposed category divided by the 
corresponding risk for the reference category. TABs were censored at the week of 
pregnancy termination and pregnancies lasting more than 22 weeks were censored at 22 
weeks. 
We selected potential confounders from a group of variables associated with SAB 
and oral contraceptive history at baseline in our data. We also considered covariates 
meeting the criteria for confounding based on a review of the literature and the 
assessment of causal graphs?8 Covariates included were maternal age, cigarette smoking, 
parity, vocational training/education, physical activity, and alcohol and caffeine 
consumption. We controlled for potential confounders that changed the HR by more than 
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5% compared with the crude HR, but were not potential causal intermediates. Both crude 
and adjusted models are presented in Table 4.3 although there was little confounding, 
except by maternal age. Models for recency and duration were mutually adjusted for each 
other. 
In secondary analyses, we assessed whether the HRs were similar for women who 
differed by waiting time to pregnancy for the index pregnancy (<6 vs. 2:6 months), 
menstrual cycle regularity (regular vs. irregular period), and maternal age ( <30 vs. 2:30). 
The etiology of pregnancy loss likely differs for early and late losses,29•30 especially by 
karyotype. We examined the relationship between the exposures and timing of losses 
(loss during <8 weeks gestation and loss during 2:8 weeks of gestation). The choice of 8 
weeks as a cut point for evaluating the timing of pregnancy loss was based on karyotype 
data showing a higher proportion of chromosomal abnormalities prior to 8 weeks. 31 
We used multiple imputation methods to impute missing covariate, exposure, and 
outcome information. 32 Covariate missingness ranged from 0% for maternal age, time to 
pregnancy, and smoking status to 6% for number of glasses of dessert wine consumed per 
week. The history of OC use data was self-reported on the baseline questionnaire and has 
some implausible and missing information. Wherever possible, existing information was 
used to determine the best method to fill in missing or implausible values. In cases where 
existing information could not be used, multiple imputation filled in any missing values. 
After using existing information to fill in some values, we were left with the following 
missing information: 19% of women did not report the most recent brand of OCs so we 
could not determine their most recent dose of estrogen or type of progestin. 13% of 
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women were missing information on recency of OC use and 7% were missing 
information on duration. We used PROC MI to create 5 imputed datasets based on 45 
variables in the imputation model. We combined beta coefficients and standard errors 
across the imputed datasets using PROC MIANALYZE. 
To assess departures from the proportional hazards assumption we plotted log-log 
survivor functions for each variable in categorical form. In the log-log survivor 
functions, parallel curves indicated proportional hazards. SAS statistical software 
(version 9.3, SAS Institute) was used for all analyses. 
4.3 RESULTS 
Among the 4,862 women who had previously used OCs and had a pregnancy after 
enrolling in the Snart Gravid study, a total of 694 (14.3%) experienced an SAB. Overall, 
26% of SABs were recorded only in the DNRP, 36% were reported only on a Snart 
Gravid follow-up questionnaire, 15% were documented in both sources and 23% were 
women who reported a pregnancy on a follow-up questionnaire but had no outcome 
information in the registries (Table 4.1 ). 
Baseline characteristics of study participants according to recency and duration of 
OC use are presented in Table 4.2. More recent OC use was associated with higher 
education, parity, lower BMI, less smoking, and regular menstrual cycles. The number of 
SABs by maternal age strata and recency and duration categories are presented in Table 
4.3. Risk of SAB tended to increase with increasing maternal age, decreased with 
increasing duration of OC use and was inconsistently related with recency of OC use. 
The median time since last OC use in the cohort was 14 months. Longer duration was 
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associated with nulliparity, smoking, higher physical activity levels, and more alcohol 
consumption. The median duration of OC use was 8 years. 
Use ofOCs within 0-1 months before conception was associated with a 19% 
decrease in risk of SAB compared with use > 1 year before conception (HR: 0.81; 95% 
CI: 0.61, 1.07) (Table 4.4). The HRs for use ofOCs within 2-6 months and 7-12 months 
of conception were 0.99 [95% CI: 0.83, 1.20] and 0.95 [95% CI: 0.77, 1.18], respectively. 
The risk of SAB <8 weeks of gestation was also lower among women who had used OCs 
within 0-1 months before conception (HR: 0.76; 95% CI: 0.52, 1.11) (Table 4.5). There 
were no consistent associations between recency of OC use and SAB that occurred at 8 
weeks or later. The relationship between more recent use of OCs and risk of SAB was 
not materially different across strata of time to pregnancy, regularity of menstrual cycles, 
or maternal age (Table 4.6). Figure 4.1 displays the association between recency of OC 
use and the risk of SAB by gestational week using restricted cubic splines. The curve 
indicates that the risk of SAB increases from 0-3 months and is mostly constant 
thereafter. 
Overall, longer duration of OC was associated with a small decrease in the risk of 
SAB. The HRs for 4-7, 8-11, and 2:12 years of OC use compared with <4 years of OC 
use were 1.05 [95% CI: 0.80, 1.37], 0.92 [95% CI: 0.71, 1.19], and 0.88 [95%CI: 0.65, 
1.19], respectively (Table 4.4). Duration ofOC use was not materially associated with 
risk of early or late SAB (Table 4.5). In sub-analyses, longer duration (2:12 years) was 
associated with an increased risk ofSAB among women < 30 years (HR: 1.37; 95% CI: 
0.88, 2.13) but with a decreased risk in women 2:30 years (HR: 0.66; 95% CI: 0.43, 1.01) 
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(Table 4.6), compared with duration <4 years. Longer duration of OC use also was 
associated with a decreased risk of SAB among women who had been trying to get 
pregnant for <6 months (HR: 0.71 95% CI: 0.45, 1.11) (Table 4.6). The restricted cubic 
spline curve indicates that the risk of SAB decreases with longer duration of OC use 
(Figure 4.2). 
Women who most recently used an OC with 4th generation progestins had 1.15 
times the risk of SAB compared with women whose most recent formulation contained a 
3rd generation progestin [95% CI: 0.92, 1.42] (Table 4.3). Generation of most recent OC 
was not associated with early SAB but 1st/2nd and 4th generation users exhibited increased 
risk oflate SAB, HRs 1.17 [95% CI: 0.81, 1.70] and 1.38 [95% CI: 0.95, 2.00], 
respectively (Table 4.5). 4th generation OC users also exhibited increased risk when they 
had a longer time to pregnancy or irregular menstrual cycles (Table 4.6). In all analyses, 
dose of estrogen in most recent OC was not consistently associated with risk of SAB. 
Estimates were unchanged when models for dose of estrogen and generation of progestin 
were adjusted for recency of OC use (data not shown). 
4.4 DISCUSSION 
In this cohort, we observed that very recent OC use (within one month of 
conception) is associated with a small decrease in risk of SAB. This finding remained 
consistent for early and late losses and across strata of maternal age, time to pregnancy, 
and menstrual cycle regularity. Longer duration of OC use may increase the risk of SAB 
for women <30 years of age but decrease the risk among women aged 30 and older. Use 
of a 4th generation progestin as most recent OC increases risk of SAB 2:8 weeks of 
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gestation. Dose of most recent OC was not appreciably related to risk of SAB. 
Our finding of decreased risk of SAB with more recent use of OCs agrees with 
several prior studies. 2•3 The observed decrease in risk associated with longer duration of 
OC use overall,4 and specifically among older women1 were also previously reported. 
The associations of specific doses of estrogen and generations of progestin in the most 
recent pills have not been examined in depth in prior analyses. Differential left-
truncation bias, which is common in other studies of SAB that recruit women who are 
already pregnant, 33 is not a problem in our study because we enrolled women prior to 
conception. 
It was not feasible to collect daily readings of human chorionic gonadotropin 
(hCG) from the participants in our cohort. This limitation is common to the vast majority 
of SAB studies and may result in missing some very early SABs. Missing early losses 
would have induced selection bias if history of OC use affected early losses differently 
than later losses, which is possible but unknown. Women who were lost to follow-up or 
became pregnant a long time after entering Snart Gravid may have had a missed SAB or 
may have resumed taking OCs between the end of follow-up and the index pregnancy 
that we analyzed. We expect that the proportion of missed losses is smaller within this 
population of pregnancy planners than among the general population because pregnancy 
planners are presumably more observant of menstrual cycles. In support of this theory, 
96% of the Snart-Gravid population used home pregnancy tests to confirm pregnancy.34 
Even with the use of multiple imputation to fill in missing and implausible 
exposure information, misclassification is still likely. The potential exposure 
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misclassification is the most serious threat to validity in this study. The misclassification 
is expected to be non-differential with respect to SAB status and would most likely bias 
the estimates of association for extreme categories of recency and duration toward the 
null. A study of self-report vs. pharmacy registry records from Sweden showed high 
levels of agreement for time since last OC use (r=0.84) and total duration of OC use 
(r=O. 78). 35 We suspect that the self-reported recency of OC use from participants in the 
Snart Gravid cohort is likely to be more accurate than the timing inferred from pharmacy 
records, which do not reveal how many of or when the prescribed pills were taken. 
Since the outcome data were collected from two data sources, independent of 
exposure information, we do not believe that dependent misclassification between 
exposure and outcome is a major concern. Nevertheless, because the exposure and 
covariates were collected using a self-administered questionnaire, there is a possibility 
that misclassification of these variables may be correlated with each other and lead to 
dependent misclassification and residual confounding?8 
The observed decrease in risk of SAB among older women with longer durations 
of OC use is biologically plausible. OCs prevent pregnancy by suppressing ovulation and 
OC users don't experience the proliferative effects that occur during the menstrual cycle 
of non-OC users. Several hypotheses invoke the theory that "healthy" oocytes are 
ovulated first and, as a woman ages, the oocytes that are left are more likely to be 
abnormal. This theory is based on evidence that older women are more likely to have 
children with chromosomal abnormalities.36 In some3741 but not all studies,42'43 a history 
of OC use was associated with delayed age at menopause which may be related to 
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preservation of ovarian reserve. The decrease in risk of SAB that was observed among 
women with OC use close to conception may be due to residual effects of OCs on 
endogenous hormones. Several studies22'23 have demonstrated a delay in the return to 
fertility after OC use. The decrease in risk of SAB among women with more recent OC 
use could also be due to reproductive fitness that would both increase the likelihood of a 
short TTP and decrease the likelihood of SAB. 
In summary, we observed that more recent OC use and longer durations of OC 
use were associated with a decreased risk of SAB. However, the association between 
duration of OC use and SAB risk differed for older vs. younger women. Dose of 
estrogen in the most recent OC formulation was unrelated to SAB risk. Our results 
suggest that recent and/or long-term OC use in the pregravid period are not associated 
with an increased risk of SAB. 
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Table 4.1 Distribution of gestational age of SABs by identification source 
Registry Snart Gravid Both SG and Missing from Gestational registries, 
age (weeks) only follow-up only registry assumed SAB b N=181 N=251a N=104 N=158 
4 4 (2 .2) 55 (21.9) 7 (6.7) 8 (5.1) 
5 13(7.2) 60 (23 .9) 13 (12 .5) 10 (6.3) 
6 . 36 (19.9 44 (17.5) 23 (22.1) 27 (17.1) 
7 38 (21 .0) 31 (12.4) 27 (26 .0) 51 (32 .3) 
8 20 (11.1) 21 (8.4) 17(16.4) 36 (22 .8) 
9 9 (5.0) 13 (5.2) 5 (4.8) 17 (10 .8) 
10 17 (9 .4) 8 (3 .2) 6 (5.8) 5 (3.2) 
11 21 (11.6) 8 (3.2 4 (3.9) 2 (1.3) 
12 11 (6.1) 7 (2.8) 2 (1 .9) 2 (1.3) 
13 3 (1.7) 1 (0.4) 
14 1 (0 .6) 3 (1.2) 
15 
16 2 (1.1) 
17 1 (0.6) 
18 3 (1.7) 
19 1 (0 .6) 
20 
21 1 (0 .6) 
•The SG follow-up questionnaires are less likely to identify later losses (>8 weeks of gestation) because 
they are conducted every two months 
bGestational age for participants who were completely missing from the registry were multiply imputed , 
frequencies presented are from the first imputation dataset. 
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Table 4.2. Age-adjusted distribution of characteristics a of 4862 women according to time 
since last OC use and duration of OC use from the first imputed dataset 
- Recency ofOC use (months) Duration ofOC use (years) 
0-1 2-6 7-12 >12 <4 4-7 8-11 ~12 
Parity 
Nulliparous 59. 1 66.1 71.7 68.2 60.0 62.8 69.0 76.6 
1 Birth 30.8 25.4 22.0 24.1 29.3 25.1 24.3 18.6 
>1 births 10.2 8.5 6.3 7.7 10.6 12.1 6.7 4.8 
Vocational Training/Education 
No vocational training 10.8 11.7 11.2 13.0 18.2 13.6 8.2 7.8 
Semi-skilled/basic training 13.1 16.4 13 .9 16.6 10.9 14.5 17.3 19.1 
Higher education (:S4 years) 50.6 47.7 53 .8 49.9 48.2 46.7 53 .6 51.9 
Higher education (>4 years) 25.5 24.2 21.1 20.6 22.7 25.2 20.9 21.1 
Smoking Status 
Non-smokers 82.7 81.1 81.5 79.1 82.5 82.5 80.4 77.9 
<10 cigarettes/day 10.5 9.2 8.8 10.4 6.8 9.3 10.0 10.7 
10 or more cigs/day 6.8 9.7 9.8 10.5 10.7 8.2 9.6 11.5 
Body Mass Index 
<20 13.1 13.6 12.5 15.9 17.3 14.5 14.2 9.7 
20-24.9 58.5 56.0 54.0 50.0 48.2 52.1 54.0 57 .2 
25-29.9 21.8 19.5 22.0 20.3 19.1 20.5 21.6 22.3 
~30 6.7 10.9 11.5 13 .8 15.4 13.0 10.2 10.8 
Alcohol categories 
0 drinks per week 31.2 29.8 28.8 31.1 38.2 31.3 27.5 25.0 
1 drink/wk 14.0 14.5 15.2 15.3 16.3 14.4 14.4 18.1 
2 drinks/wk 13 .9 14.7 15.5 15.8 13.9 15.5 15 .5 13.8 
3-6 drinks/wk 31.6 29.9 28.1 28.1 23.0 29.1 30.8 32.8 
~7 drinks/wk 9.2 11.2 12.4 9.7 8.6 9.8 11.8 11.1 
METs Categories 
<10METs 14.1 14.6 16.8 15.7 16.0 14.9 14.7 15.1 
10-19 METs 31.2 32.3 31.3 32.7 36.3 31.8 32.9 31.2 
20-39 METs 39.8 36.0 36.1 34.4 32.7 36.7 35.0 34.6 
~40 METs 14.9 17.0 15.8 17.2 15.1 16.6 17.3 19.1 
Time to pregnancy ~6 months 0 12.4 86.6 78.9 57.4 55.9 55.2 51.2 
Re Jar Period 82.9 78.8 70.0 73 .2 70.2 73 .7 76.4 79.0 
a Characteristics are presented as percentages within levels of caffeine consumption based on the 
first imputation dataset, and are standardized to the age distribution of the cohort at baseline. 
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Table 4.3 Number of spontaneous abortions and gestational weeks a at risk by maternal age and duration and recency of OC 
use. 
Recency ofOC use (months) Duration ofOC use (years) 
Age (Years) 0-1 2-6 7-12 >12 <4 4-7 8-11 >12 Total 
:::;20 
SAB 3 7 3 6 6 13 0 0 19 
Gestational weeks 162 520 462 975 925 1063 110 21 2119 
Rate/1000 GW 18.5 13 .5 6.5 6.2 6.5 12.2 0 0 9.0 
21-24 
SAB 8 23 19 38 9 62 17 0 88 
Gestational weeks 1307 4047 2959 6203 2722 8419 3194 181 14516 
Rate/1000 GW 6.1 5.7 6.4 6.1 3.3 7.4 5.3 0 6.1 
25-28 
SAB 18 61 42 109 29 60 Ill 30 230 
Gestational weeks 3982 8964 6630 14967 3614 10220 17688 ~021 34543 
Rate/1000 GW 4.5 6.8 6.3 7.3 8.0 5.9 6.3 9.9 6.7 
29-32 
SAB 16 43 38 113 24 48 92 46 210 
Gestational weeks 2841 7086 4885 14154 2276 6161 13109 7420 28966 
Rate/1000 GW 5.6 6.1 7.8 8.0 10.5 7.8 7.0 6.2 7.2 
33-36 
SAB 11 31 11 61 12 29 44 29 114 
Gestational weeks 1161 2716 1967 6112 1043 2521 4739 3653 11956 
Rate/1000 GW 9.5 11.4 5.6 10.0 11.5 11.5 9.3 7.9 9.5 
?_37 
SAB I 8 6 18 7 7 11 8 33 
Gestational weeks 246 718 484 1512 499 818 835 808 2960 
Rate/1000 GW 4.1 11.1 12.4 11.9 14.0 8.6 13 .2 9.9 11.1 
Age-Standardized rate 6.0 7.3 6.9 7.8 8.7 7.6 6.8 6.8 
Age-Standardized rate difference -1.8 -0.5 -0.9 [ref] [ref] -1.0 -1.9 -1.9 
95% CI -3.5, 0.0 -1.9, 0.9 -2.4, 0.6 -3.2, 1.1 -3.9, 0.2 -4.3, 0.6 
Standardized rate ratio 0.77 0.94 0.89 [ret] [ret] 0.88 0.79 0.79 
95% CI 0.58J .03 
-
0.78, J.12 0.72, 1.09 0.68, 1.14 0.61, 1.01 0.58, 1.07 
--
aFrom the first imputation dataset. 
-
1,0 
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Table 4.4. Hazard ratios for the association of SAB with recency and duration of OC use and type of most recent pill 
N Total Adjustedb 
SABa GWsa Crude HR [95% CI] 
Recency ofOC use (months)c 
0-1 57 9699 0.76 0.81 [0.61, 1.07] 
2-6 173 24051 0.94 0.99 [0.83 , 1.20] 
7-12 119 17387 0.91 0.95 [0.77, 1.18] 
>12 345 43923 1.00 [Reference] 
Duration ofOC use (yearst 
<4 87 11079 1.00 [Reference] 
4-7 219 29202 1.02 1.05 [0.80, 1.37] 
8-11 275 39675 0.93 0.92 [0.71, 1.19] 
~12 113 15104 1.00 0.88 [0.65, 1.19] 
Generation of progestin 
l st;2nd 142 19376 1.04 1.00 [0.79, 1.26] 
3rd 377 52958 1.00 [Reference] 
4th 120 14492 1.14 1.15 [0.92, 1.42] 
other 55 8234 0.91 0.90 [0.67, 1.20] 
Dose of estrogen 
No Estrogen 17 2145 1.15 1.07 [0.74, 1.54] 
<30 )lg 407 56416 1.00 [Reference] 
~30 )lg 89 13267 0.93 0.91 [0.73, 1.13] 
other 51 7827 0.88 0.87 [0.65, 1.15] 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
b Adjusted for maternal age, physical activity, parity, vocational training/education, alcohol consumption, caffeine consumption, and 
smoking. 
cEstimates for recency and duration are mutually adjusted for each other. 
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Table 4.5. Hazard ratios for early (<8 weeks) or late SABin relation to recency and duration ofOC use and type of most recent 
pill 
Late SAB ?.8 weeks 
N Total Crude N Total Crude Adjustedb SAB" GWs" SAB" GWs" HR [95% CI] 
Recency (monthsl 
0-1 34 21 7 0.70 0.76 [0.52, 1.11] 23 9482 0.86 0.87 [0.55, 1.39] 
2-6 110 694 0.95 1.01 [0.80, 1.27] 63 23357 0.93 0.97 [0.70, 1.33] 
7-12 83 527 0.97 1.03 [0.77, 1.38] 36 16860 0.78 0.81 [0.51 , 1.28] 
>12 220 1458 1.00 [Reference] 125 42465 1.00 [Reference] 
Duration (years l 
<4 60 137 1.00 [Reference] 27 10682 1.00 [Reference] 
4-7 137 851 0.97 1.00 [0.70, 1.42] 82 28351 1.15 1.15 [0.72, 1.86] 
8-11 170 1093 0.86 0.87 [0.62, 1.21] 105 38582 1.07 1.02 [0.64, 1.62] 
?.12 80 555 0.95 0.83 [0.56, 1.23] 33 14549 1.10 0.98 [0.53, 1.79] 
Generation of progestin 
1st/2nd 86 571 0.96 0.92 [0.69, 1.21 ] 5 2074 1.21 1.1 7 [0.81 , 1.70] 
3'd 257 1644 1. 00 [Reference] 145 54729 1.00 [Reference] 
4th 72 461 1.04 1.04 [0.79, 1.36] 33 12886 1.36 1.38 [0.95, 2.00] 
other 32 220 0.73 0.72 [0.47, 1.10] 21 7619 1.28 1.26 [0.79, 2.00] 
Dose of estrogen 
No Estrogen 12 71 1.22 1.16 [0.70, 1.91] 56 18805 0.99 
<30 llg 262 1687 1.00 [Reference] 120 51314 
~30 llg 56 381 0.89 0.86 [0.65 , 1.15] 48 14031 0.99 
other 30 208 0.75 0.74 0.48, 1.14 23 8014 1.13 
"Frequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted model includes maternal age, physical activity, parity, vocational training/education, alcohol consumption, caffeine 
consumption, and smoking. 
cEstimates for recency and duration are mutually adjusted for each other. 
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Table 4.6. Hazard ratios for the association between SAB and recency and duration of OC use and type of most recent pill 
stratified by time to r regnancy, menstrual cycle regularity and age. 
N Total TTP <6 monthsb N SABa GWsa SABa 
Recency (monthst 
0-1 57 9699 0.85 [0.59, 1.22] 0 
2-6 153 21044 1.02 [0.75, 1.37] 20 
7-12 20 2314 1.38 [0.82, 2.32] 99 
>12 76 9398 1.00 [Reference] 269 
Duration (yearst 
<4 41 4652 1.00 [Reference] 46 
4-7 95 12743 0.90 [0.60, 1.36] 124 
8-11 120 18010 0.81 [0.54, 1.20] 155 
:::::12 50 7050 0.71 [0.45, 1.11] 63 
Generation of progestin 
1 st;2nd 68 8843 0.98 [0. 71' 1.35] 74 
3rd 173 24008 1.00 [Reference] 204 
4th 42 6294 0.94 [0.66, 1.33] 78 
other 23 3310 0.95 [0.61, 1.48] 32 
Dose of estrogen 
No Estrogen 9 1355 1.03 [0.61, 1.76] 8 
<30 flg 181 25478 1.00 [Reference] 226 
:::::30 flg 35 6285 0.80 [0.55, 1.16] 54 
other 22 3182 0.92 [0.59, 1.43] 29 
aFrequencies and gestational weeks (GW) from the ftrst imputation dataset 
Total 
GWsa 
0 
3007 
15073 
34525 
6427 
16459 
21665 
8054 
10533 
28950 
8198 
4924 
790 
30938 
6982 
4645 
TTP :::::6 monthsb 
0.88 [0.56, 1.39] 
0.88 [0.69, 1.11 ] 
1.00 [Reference] 
1.00 [Reference] 
1.16 [0.80, 1.68] 
1.03 [0.71, 1.48] 
1.01 [0.67' 1.52] 
1.02 [0. 72, 1.45] 
1.00 [Reference] 
1.29 [0.98, 1. 70] 
0.86 [0.58, 1.28] 
1.11 [0.67, 1.84] 
1.00 [Reference] 
0.99 [0.74, 1.33] 
0.83 [0.57, 1.21] 
bAdjusted model includes maternal age, physical activity, parity, vocational training/education, alcohol consumption, caffeine 
consumption, and smoking. 
cEstimates for recency and duration are mutually adjusted for each other. 
Table 4.6 continued. Hazard ratios for the association between SAB and recency and duration of OC use and type of most 
recent 2ill, stratified by menstrual cycle regularity 
N Total Regular periodb N Total Irregular periodb SAB" GWs" SAB" GWs" 
Recency (monthst 
0-1 46 8062 0.76 [0.55, 1.04] 11 1637 0.91 [0.48, 1.75] 
2-6 138 18865 0.97 [0.78, 1.19] 35 5186 1.03 [0.68, 1.56] 
7-12 83 12147 0.89 [0.69, 1.15] 36 5240 1.09 [0.72, 1.65] 
>12 270 32169 1.00 [Reference] 75 11754 1.00 [Reference] 
Duration (years t 
<4 69 7463 1.00 [Reference] 18 3616 1.00 [Reference] 
4-7 156 21502 0.88 [0.64, 1.19] 63 7700 1.71 [0.98, 2.98] 
8-11 218 30206 0.80 [0.59, 1.07] 57 9469 1.34 [0.75, 2.39] 
2:12 94 12072 0.77 [0.55, 1.07] 19 3032 1.30 [0.62, 2.72] 
Generation of progestin 
1 st;2nd 121 14888 1.03 [0.81, 1.31] 21 4488 0.84 [0.47' 1.51] 
\0 
3'd 298 39812 1.00 [Reference] 79 13146 1.00 [Reference] 
w 4th 78 10656 0.97 [0.74, 1.26] 42 3836 1.79 [1.21, 2.64] 
other 40 5887 0.90 [0.64, 1.26] 15 2347 0.95 [0.52, 1.74] 
Dose of estrogen 
No Estrogen 14 1593 1.17 [0.74, 1.85] 3 552 0.70 [0.26, 1.86] 
<30 f..lg 305 42334 1.00 [Reference] 102 14082 1.00 [Reference] 
2:30 f.!g 73 10155 0.95 [0.73, 1.24] 16 3112 0.72 [0.41, 1.28] 
other 38 5600 0.91 [0.65, 1.26] 13 2227 0. 78 [0.44, 1.40] 
"Frequencies and gestational weeks (GW) from the first imputation dataset 
b Adjusted model includes maternal age, physical activity, parity, vocational training/education, alcohol consumption, caffeine 
consumption, and smoking. 
cEstimates for recency and duration are mutually adjusted for each other. 
Table 4.6 continued. Hazard ratios for the association between SAB and recency and duration of OC use and type of most 
recent pill stratified by age. 
N Total Age<30b N Total Ag~30b SABa GWsa SABa GWsa 
Recency (months)" 
0-1 32 6390 0.76 [0.52, 1.12] 25 3309 0.83 [0.54, 1.29] 
2-6 103 16076 0.96 [0.75, 1.23] 70 7975 1.02 [0.77, 1.35] 
7-12 74 11581 0.97 [0.73, 1.27] 45 5806 0.89 [0.64, 1.25] 
>12 182 26322 1.00 [Reference] 163 17601 1.00 [Reference] 
Duration (years)" 
<4 49 7846 1.00 [Reference] 38 3233 1.00 [Reference] 
4-7 145 21692 1.16 [0.82, 1.63] 74 7510 0.92 [0.61, 1.40] 
8-11 156 25850 1.06 [0.75, 1.49] 119 13825 0.78 [0.53 , 1.15] 
~12 41 4981 1.37 [0.88, 2.13] . 72 10123 0.66 [0.43 , 1.01] 
Generation of progestin 
1st/2nd 65 10792 0.95 [0.72, 1.25] 77 8584 1.07 [0.74, 1.53] 
\0 3rd 221 35099 1.00 [Reference] 156 17859 1.00 [Reference] ~ 4th 72 9617 1.18 [0.90, 1.55] 48 4875 1.12 [0.79, 1.60] 
other 33 4861 1.05 [0.72, 1.53] 22 3373 0.74 [0.43 , 1.18] 
Dose of estrogen 
No Estrogen 10 1135 1.08 [0.65, 1.79] 7 1010 1.09 [0.66, 1.80] 
<30 jlg 258 38778 1.00 [Reference] 149 17638 1.00 [Reference] 
~30 jlg 41 8082 0.75 [0.53, 1.06] 48 5185 1.09 [0.79, 1.51] 
other 31 4659 0.99 [0.68, 1.43] 20 3168 0.74 [0.47, 1.16] 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted model includes maternal age, physical activity, parity, vocational training/education, alcohol consumption, caffeine 
consumption, and smoking. 
cEstimates for recency and duration are mutually adjusted for each other. 
Figure 4.1. Relationship between recency of OC use in months and risk of SAB fitted by 
restricted cubic splines. 
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Figure 4.2. Relationship between duration of OC use in years and risk of SAB fitted by 
restricted cubic splines. 
2 
I 
..._.... 
0 
...... 
n:l 
0:::: 
"0 
.... 
n:l 
N 
n:l 
I 
2.0 
1.9 
1.8 
1.7 
1.6 
1.5 
1.4 
1.3 
1.2 
1.1 
1.0 
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0 
' 
' 
' 
' 
' 
' 
' 
' ... , 
',, 
.......... 
'~-------------~~~ 
-... 
4 8 12 
Duration of OC use (years) 
...... 
...... 
Adjusted for maternal age, parity, BMI, alcohol consumption, smoking, vocational 
training/education, recency of OC use, and caffeine consumption. 
4 knots at 3, 6, 10, and 13 years. 
96 
...... 
......... 
16 
4.5 REFERENCES 
1. Ford JH, MacCormac L. Pregnancy and lifestyle study: the long-term use of the 
contraceptive pill and the risk of age-related miscarriage. Hum Reprod. Jun 
1995; 1 0(6): 1397-1402. 
2. Sackoff J, Kline J, Susser M. Previous use of oral contraceptives and spontaneous 
abortion. Epidemiology. Jul1994;5(4):422-428. 
3. Harlap S, Shiono PH, Ramcharan S. Spontaneous foetal losses in women using 
different contraceptives around the time of conception. International journal of 
epidemiology. Mar 1980;9(1):49-56. 
4. Rothman KJ. Fetal loss, twinning and birth weight after oral-contraceptive use. 
The New England journal of medicine. Sep 1 1977;297(9):468-471. 
5. Garcia-Enguidanos A, Martinez D, Calle ME, LunaS, Valero de Bernabe J, 
Dominguez-Rojas V. Long-term use of oral contraceptives increases the risk of 
miscarriage. Fertility and sterility. Jun 2005;83(6): 1864-1866. 
6. Vessey M, Meisler L, Flavel R, Yeates D. Outcome of pregnancy in women using 
different methods of contraception. British journal of obstetrics and gynaecology. 
Jul1979;86(7):548-556. 
7. Risch HA, Weiss NS, Clarke EA, Miller AB. Risk factors for spontaneous 
abortion and its recurrence. American journal of epidemiology. Aug 
1988; 128(2):420-430. 
8. Jellesen R, Strandberg-Larsen K, Jorgensen T, Olsen J, Thulstrup AM, Andersen 
AM. Maternal use of oral contraceptives and risk of fetal death. Paediatric and 
perinatal epidemiology. Jul 2008;22( 4):334-340. 
9. Blohm F, Friden B, Milsom I. A prospective longitudinal population-based study 
of clinical miscarriage in an urban Swedish population. BJOG : an international 
journal of obstetrics and gynaecology. Jan 2008; 115(2): 176-182; discussion 183. 
10. Streuli I, Fraisse T, Pillet C, Ibecheole V, BischofP, de Ziegler D. Serum 
antimullerian hormone levels remain stable throughout the menstrual cycle and 
after oral or vaginal administration of synthetic sex steroids. Fertility and sterility. 
Aug 2008;90(2):395-400. 
11. Li HW, Wong CY, Yeung WS, Ho PC, Ng EH. Serum anti-mullerian hormone 
level is not altered in women using hormonal contraceptives. Contraception. Jun 
2011;83(6):582-585. 
97 
12. Nassaralla CL, Stanford JB, Daly KD, Schneider M, Schliep KC, Fehring RJ. 
Characteristics of the menstrual cycle after discontinuation of oral contraceptives. 
J Womens Health (Larchmt). Feb 2011;20(2):169-177. 
13. Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ. Circulating levels 
of sex hormones and their relation to risk factors for breast cancer: a cross-
sectional study in 1092 pre- and postmenopausal women (United Kingdom). 
Cancer causes & control: CCC Jan 2001;12(1):47-59. 
14. Blackmore KM, Wong J, Knight JA. A cross-sectional study of different patterns 
of oral contraceptive use among premenopausal women and circulating IGF-1: 
implications for disease risk. BMC women's health. 2011; 11 : 15. 
15. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital 
and health statistics. Series 23, Datafrom the National Survey of Family Growth. 
Aug 2010(29): 1-44. 
16. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive 
study across five European countries. The European journal of contraception & 
reproductive health care : the official journal of the European Society of 
Contraception. Jun 2004;9(2):57-68. 
17. Huybrechts KF, Mikkelsen EM, Christensen T, et al. A successful implementation 
of e-epidemiology: the Danish pregnancy planning study 'Snart-Gravid'. 
European journal of epidemiology. May 2010;25(5):297-304. 
18. Mikkelsen EM, Hatch EE, Wise LA, Rothman KJ, Riis A, Sorensen HT. Cohort 
profile: the Danish Web-based Pregnancy Planning Study--'Snart-Gravid'. 
International journal of epidemiology. Aug 2009;38(4):938-943. 
19. Rothman KJ, Mikkelsen EM, Riis A, Sorensen HT, Wise LA, Hatch EE. 
Randomized trial of questionnaire length. Epidemiology. Jan 2009;20(1) :154. 
20. Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB. Validation of the 
Danish Birth Registration. Journal of clinical epidemiology. Aug 1996;49(8):893-
897. 
21. Lohse SR, Farkas DK, Lohse N , et al. Validation of spontaneous abortion 
diagnoses in the Danish National Registry of Patients. Clinical epidemiology. 
2010;2:247-250. 
22. Mikkelsen EM, Riis AH, Wise LA, Hatch EE, Rothman KJ, Sorensen HT. Pre-
gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort 
study. Hum Reprod. May 2013;28(5):1398-1405. 
98 
23. Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H. Fertility after 
discontinuation of treatment with an oral contraceptive containing 30 microg of 
ethinyl estradiol and 2 mg of dienogest. Fertility and sterility. Jun 
2006;85(6): 1812-1819. 
24. Wilson NM, Laursen M, Lidegaard 0. Oral contraception in Denmark 1998-2010. 
Acta obstetricia et gynecologica Scandinavica. Jul 20 12;91 (7): 810-815. 
25. Jacobs DR, Jr., Ainsworth BE, Hartman TJ, Leon AS. A simultaneous evaluation 
of 10 commonly used physical activity questionnaires. Medicine and science in 
sports and exercise. Jan 1993;25(1):81-91. 
26. Durrleman S, Simon R. Flexible regression models with cubic splines. Statistics 
in medicine. May 1989;8(5):551-561. 
27. Themeau TM, Grambsch PM. Modeling survival data: extending the Cox Model: 
Springer; 2000. 
28. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: 
Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008. 
29. United States. Congress. Office ofTechnology Assessment. Reproductive health 
hazards in the workplace. Washington, D.C.: Congress of the U.S. For sale by the 
Supt. ofDocs., U.S. G.P.O.; 1985. 
30. Savitz DA, Hertz-Picciotto I, Poole C, Olshan AF. Epidemiologic measures of the 
course and outcome ofpregnancy. Epidemiologic reviews. 2002;24(2):91-101. 
31. Klein J, Stein Z. Epidemiology of chromosomal anomalies in spontaneous 
abortion: prevalence, manifestation and determinants. In: Bennett MJ, Edmonds 
DK, eds. Spontaneous and recurrent abortion. Oxford, UK: Blackwell Scientific 
Publications; 1987 :p. 29. 
32. Zhou XH, Eckert GJ, Tierney WM. Multiple imputation in public health research. 
Statistics in medicine. May 15-30 2001;20(9-10):1541-1549. 
33 . Howards PP, Hertz-Picciotto I, Poole C. Conditions for bias from differential left 
truncation. American journal of epidemiology. Feb 15 2007;165(4):444-452. 
34. Wise LA, Mikkelsen EM, Rothman KJ, et al. A prospective cohort study of 
menstrual characteristics and time to pregnancy. American journal of 
epidemiology. Sep 15 2011;174(6):701-709. 
99 
35. Norell SE, Boethius G, Persson I. Oral contraceptive use: interview data versus 
pharmacy records. International journal ofepidemiology. Dec 1998;27(6):1033-
1037. 
36. Erickson JD. Down syndrome, paternal age, maternal age and birth order. Annals 
of human genetics. Jan 1978;41(3):289-298. 
37. Palmer JR, Rosenberg L, Wise LA, Horton NJ, Adams-Campbell LL. Onset of 
natural menopause in African American women. American journal of public 
health. Feb 2003;93(2):299-306. 
38. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural 
menopause in a multiethnic sample of midlife women. American journal of 
epidemiology. May 1 2001;153(9):865-874. 
39. Gold EB, Crawford SL, Avis NE, et al. Factors related to age at natural 
menopause: longitudinal analyses from SWAN. American journal of 
epidemiology. Jul1 2013;178(1):70-83. 
40. Khaw KT. Epidemiology of the menopause. British medical bulletin. Apr 
1992;48(2):249-261. 
41. Garrido-Latorre F, Lazcano-Ponce EC, Lopez-Carrillo L, Hernandez-Avila M. 
Age of natural menopause among women in Mexico City. International journal of 
gynaecology and obstetrics: the official organ of the International Federation of 
Gynaecology and Obstetrics. May 1996;53(2): 159-166. 
42. Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors 
influencing the age at natural menopause. Journal of chronic diseases. 
1987;40(11):995-1002. 
43. van Keep PA, Brand PC, Lehert P. Factors affecting the age at menopause. 
Journal ofbiosocial science. Supplement. 1979(6):37-55. 
100 
5 CONCLUSION 
The studies presented in this dissertation have addressed three potential risk 
factors for spontaneous abortion (SAB) in a prospective cohort of pregnancy planners in 
Denmark; extremes of body size, caffeine consumption, and history of oral contraceptive 
use. 
Conducting the studies in Denmark enabled us to link self-reported questionnaire 
information from participants in the Snart Gravid study with the Danish Medical Birth 
Registry (DMBR) and Danish National Registry ofPatients (DNRP), using their Civil 
Personal Registration (CPR) number. The combination of these sources allowed us to 
capture both early and late SAB and avoid left truncation bias, an advantage over most 
previous studies. A validation study ofDNRP data found that 30% of self-reported SABs 
were not registered in the DNRP; 1 however, this study used data from before the registry 
started to include data from outpatient clinics ( <1995). In a comparison of the DNRP to 
individual medical records, another study found a positive predictive value of98.7%.2 
Based on these studies, we believe that the combination of self-report and registry-
identified SABs has provided us with a comprehensive and valid estimate of the total 
number of SABs in this population. Of course, it is possible that some early SABs were 
missed before the clinical pregnancy was identified. We expect that this proportion would 
be small because 96% of the women who conceived in Snart Gravid used pregnancy tests 
to detect their pregnancy.3 
In study 1, we examined extremes of body size as measured by body mass index 
(BMI), waist circumference (WC), waist-to-hip ratio (WHR), height, and location where 
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participants tended to gain weight in relation to risk of SAB. We found that obesity was 
associated with an increased risk of SAB, a result consistent with prior studies,4-9 
especially for losses before 8 weeks of gestation. Increasing WHR and increasing height 
were associated with a decreased risk of SAB and WC and tendency to gain weight were 
not associated with SAB. There was a potential for exposure misclassification in this 
analysis because body size parameters were self-reported. Height and weight 
measurements were validated by a previous analysis of this cohort and were highly 
concordant with physical exam measurements (r=0.96). 10 Self-reported data on waist and 
hip circumferences were not validated in this cohort. Other validation studies have 
demonstrated that women tend to underestimate both measurements. 11 We expect that the 
exposure misclassification would be nondifferential and bias the observed associations in 
extreme categories toward the null and intermediate categories in an unpredictable 
direction. This study was the first to our knowledge to examine the association between 
measures of central adiposity, height, and body fat distribution and risk of SAB. 
The second study evaluated the association between caffeine and caffeinated 
beverage consumption preconception and during early pregnancy and the risk of 
subsequent SAB. We found that women who consumed more cups of coffee per day 
before pregnancy had a slightly higher risk of SAB. Higher levels of caffeine 
consumption during early pregnancy were also associated with a slightly increased risk of 
SAB, a finding consistent with several other prospective studies. 12-16 Although this 
association has been examined before, 17 prior analyses have produced conflicting results. 
Our study improves on previous study designs by eliminating problems of left truncation 
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bias and recall bias as well as examining both preconception and early pregnancy 
consumption of caffeine overall and individual caffeinated beverages. Limitations also 
experienced by our examination included potential for exposure misclassification, 
residual confounding, especially from smoking, and nondifferential misclassification of 
exposure that we discussed in detail in chapter 3. 
Study 3 assessed the relationship between history of oral contraceptive (OC) 
exposure-time since last use and duration of use, and formulation of the most recent 
pill-and risk of SAB. We found that more recent use and longer duration of OC use 
were independently associated with a decreased risk of SAB. When stratified by 
maternal age, younger women (<30 years) had an increased risk ofSAB with longer 
duration but older women (2:30 years) had a decreased risk of SAB. When we assessed 
the dose of estrogen and the type of progestin in the most recent OC formulation, we 
found that dose of estrogen and use of a 1 stnnct or 3 rd generation of progestin were not 
related to risk of SAB. Use of an OC with drospirenone (a 4th generation progestin) as 
the most recent formulation may be associated with an slightly increased risk of SAB. 
The observed results affirm studies that found a decreased risk among women who used 
OCs within 0-1 months before conception18'19 and other studies that found a decreased 
risk among women with a longer duration of OC use.20 '21 Our study provides a more 
comprehensive analysis of history of OC use by including information about risk of SAB 
in relation to most recent pill formation and also avoids the potential for left truncation 
bias. The exposure in this study was self-reported by participants and we observed some 
implausible and missing information. We used existing information and multiple 
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imputation to best approximate the true data but exposure misclassification may still exist 
and would likely bias the estimates of association in extreme categories of the exposure 
toward the null. We are encouraged that exposure misclassification may be small in this 
study because a previous validation of self-reported data from Sweden using a 
prescription registry found good agreement between the two sources.22 Although we are 
unable to postulate about the exact mechanisms that may link history of OC use and 
SAB, the high prevalence of OC use23 '24 makes this an important exposure to study. 
In summary, the studies included in this dissertation provided information about 
risk factors for SAB from a cohort of pregnancy planners where we were able to capture 
many early losses and avoid some common biases present in most other analyses. We 
were able to confirm prior results that observed an increase in risk of SAB associated 
with higher BMI and higher consumption of caffeine during early pregnancy and a 
decrease in risk of SAB associated with more recent use of OCs and also longer duration 
ofOC use. 
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APPENDIX 
Appendix Table 1. Hazard ratios for the association between body size characteristics and 
SAB among women with a known pregnancy outcome. 
Exposure N Total Adjusted model 
SABa GWsa HR [95% CI]b 
Body Mass Index (kg/m2) 
<20 86 
20-24 294 
25-29 107 
2:30 82 
14835 
52336 
20483 
11487 
1.03 [0.81, 1.31] 
1.00 [Reference] 
0.92 [0.73, 1.15] 
1.25 [0.97, 1.61] 
Waist circumference 
<75 em 156 
75-79 em 126 
80-86 em 114 
2:87 em 173 
25195 
22848 
22855 
28243 
1. 00 [Reference] 
0.90 [0. 70, 1.15] 
0.79 [0.60, 1.04] 
0.96 [0.75, 1.24] 
Waist-to-hip ratio 
<0.75 143 
0.75-0.79 140 
0.80-0.84 128 
2:0.85 158 
Height 
<166 em 183 
166-169 em 135 
170-173 em 128 
2:174cm 123 
20731 
24065 
24430 
29915 
31201 
20836 
22757 
24347 
1.00 [Reference] 
0.88 [0.65, 1.18] 
0.77 [0.54, 1.10] 
0.80 [0.58, 1.09] 
1.00 [Reference] 
1.09 [0.87' 1.3 7] 
0.95 [0.76, 1.20] 
0.86 [0.68, 1.08] 
Location of weight gain 
Equally all over 161 27204 1.00 [Reference] 
Waist! stomach 220 40415 0.92 [0.75, 1.12] 
Hips/ thighs 156 26467 1.01 [0.81, 1.26] 
Does not gain weight 23 4173 0.92 [0.59, 1.42] 
Chest/shoulders 9 882 1.33 [0.57,3.10] 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
b Adjusted model includes maternal age, physical activity, caffeine consumption, parity, vocational 
training/education, alcohol consumption, and smoking. 
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Appendix Table 2. Hazard ratios for risk of SAB and the relationship to preconception 
and early pregnancy caffeine consumption among women with a known pregnancy 
outcome. 
Preconception Early Pregnancy 
N Total Adjustedb N . Total Adjustedb 
SABa GWa HR [95% CI] SABa GWa HR [95% CI] 
Caffeine 
(mg/day) 
<100 262 48034 1.00 [Reference] 300 65555 1.00 [Reference] 
100-199 85 17220 0.90 [0. 70, 1.15] 71 10279 1.70 [1.17, 2.47] 
200-299 86 13315 1.16 [0.90, 1.50] 133 15144 1.58 [ 1.00, 2.49] 
2:300 136 20571 1.10 [0.88, 1.38] 65 8162 1.19 [0.50, 2.82] 
Coffee 
(cups/day)" 
0 235 42843 1.00 [Reference] 371 76814 1.00 [Reference] 
<1-1 136 27813 0.97 [0 .80, 1.17] 180 18402 1.46 [0.84, 2.53] 
2 108 15633 0.98 [0.72, 1.35] 18 3924 0.60 [0.19, 1.90] 
2:3 
90 12851 1.32 [0.92, 1.89] 
Cola 
(servings/day)" 
0 251 35794 1.00 [Reference] 520 90864 1.00 [Reference] 
<1-1 346 65573 0.92 [0.77, 1.10] 48 7712 0.89 [0.51 ' 1.56] 
2:2 8 1070 1.14 [0.56, 2.33] 1 564 
Black tea 
(cups/day)" 
0 330 54917 1.00 [Reference] 449 83642 1.00 [Reference] 
<1-1 227 41018 0.95 [0.80, 1.13] 118 14093 1.52 [1.15, 2.02] 
2:2 12 3205 0.62 [0.35 , 1.12] 2 1405 0.50 [0.12, 2.01] 
HerbaVGreen tea 
(cups/ day)" 
0 365 61495 1.00 [Reference] 441 81035 
<1-1 185 33250 0.97 [0.81' 1.17] 124 15747 
>2 19 4395 0.73 0.46, 1.17] 4 2358 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
b Adjusted model includes maternal age, physical activity, parity, vocational training/education, 
smoking, and prior spontaneous abortion. The preconception model also includes alcohol 
consumption. 
cEstimates for coffee, cola, and tea are mutually adjusted for each other. 
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Appendix Table 3. Hazard ratios for the association between the joint effect of smoking 
and caffeine consumption and SAB 
Caffeine <200 mg/day; nonsmoker 
Caffeine <200 mg/day; smoker 
Caffeine 200+ mg/day; nonsmoker 
Caffeine 200+ mg/day; smoker 
"From the first imputation dataset. 
N" 
SAB 
371 
78 
199 
84 
Preconception 
Adjustedb 
HR[95% CI] 
[Reference] 
1.07 [0.83, 1.37] 
1.09 [0.91, 1.31] 
1.39 [1.09, 1.78] 
Early Pregnancy 
N" 
SAB 
390 
95 
178 
69 
Adjustedb 
HR [95% CI] 
[Reference] 
2.11 [1.46, 3.04] 
1.45 [0.93, 2.27] 
1.85 [1.06, 3.24] 
b Adjusted model includes maternal age, physi.cal activity, parity, vocational training/education, 
smoking, and prior spontaneous abortion. The preconception model also includes alcohol 
consumption. 
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A:Q:Qendix Table 4. Distribution of most recent brand of OC 
Brand Name Na % Dose of Generation of Estrogenb Progestinc 
Trinovum 7 0.2 High Gen 1 
Cilest 429 10.6 High Gen2 
Neogynon 21 0.5 High Gen2 
Triminetta 32 0.8 High Gen2 
Trinordiol 16 0.4 High Gen2 
Triquilar 32 0.8 High Gen2 
Gracia} 29 0.7 High Gen3 
Miligest 20 0.5 High Gen3 
Mil vane 88 2.2 High Gen3 
Malon etta 49 1.2 Low Gen2 
Microgyn 36 0.9 Low Gen2 
Desorelle 105 2.6 Low Gen3 
Gestoden/Ethinyl estradiol 31 0.8 Low Gen3 
Gestonette 402 9.9 Low Gen3 
Harmonet 127 3.1 Low Gen3 
Lindynette 411 10.1 Low Gen3 
Marvel on 74 1.8 Low Gen3 
Mercilon 206 5.1 Low Gen3 
Minulet 229 5.6 Low Gen3 
N oriday "Orifarm" 6 0.2 Low Gen3 
Novynette 527 13.0 Low Gen3 
Yasmin 677 16.7 Low Gen4 
Mini-Pe 56 1.4 None Gen 1 
Cerazette 55 1.4 None Gen3 
Other 393 9.7 Other Other 
a Pre-imputation; N missing=804 
bLow dose: <30 micrograms; High dose: ~30 micrograms 
cGeneration 1: norethindrone; generation 2: norgestrel, levonorgestrel; generation 3: desogestrel, 
gestodene; generation 4: drospirenone 
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Appendix Table 5. Hazard ratios for the association between preconception oral 
contraceptive use and SAB among women with a known pregnancy outcome. 
Recency of OC use 
(monthst 
N Total 
SABa GWsa 
0-1 54 
2-6 153 
7-12 92 
> 12 237 
9655 
23921 
17180 
43166 
Adjusted 
HR [95% CI] 
1.12 [0.83, 1.52] 
1.29 [1.04, 1.58] 
1.09 [0.85, 1.39] 
1.00 [Reference] 
Duration of OC use (years t 
<4 75 
4-7 164 
8-11 213 
2:12 84 
11003 
28811 
39208 
14900 
1.00 [Reference] 
0.91 [0.67, 1.23] 
0.83 [0.62, 1.11] 
0.75 [0.54, 1.06] 
Generation of progestin 
1st/2nd 107 
3rd 301 
4th 91 
other 37 
Dose of estrogen 
19145 
52314 
14298 
8165 
0.91 [0.72, 1.15] 
1.00 [Reference] 
1.14 [0.90, 1.44] 
0. 78 [0.54, 1.11] 
No Estrogen 15 2131 1.01 [0.66, 1.53] 
<30 1-1g 317 55767 1.00 [Reference] 
2:30 1-lg 66 13099 0.89 [0.69, 1.15] 
other 35 7714 0.77 [0.55, 1.09] 
aFrequencies and gestational weeks (GW) from the first imputation dataset 
bAdjusted model includes maternal age, physical activity, parity, vocational training/education, 
alcohol consumption, caffeine consumption, and smokirig. 
cEstimates for recency and duration are mutually adjusted for each other. 
112 
BIBLIOGRAPHY 
Abrams B, Heggeseth B, RehkopfD, Davis E. Parity and body mass index in US women: 
a prospective 25-year study. Obesity (Silver Spring). Aug 2013;21(8):1514-1518. 
Armstrong BG, McDonald AD, Sloan M. Cigarette, alcohol, and coffee consumption and 
spontaneous abortion. American journal of public health. Jan 1992;82(1):85-87. 
Atay GA, Arsan S, Atasay B, Ensari A, Aysev D. The possible role of intrauterine 
infections in unexplained second trimester abortions and macerated stillbirths: a 
study from a single center. Journal of perinatology: official journal of the 
California Perinatal Association. Nov 2004;24(11):679-685. 
Bech BH, Nohr EA, Vaeth M, Henriksen TB, Olsen J. Coffee and fetal death: a cohort 
study with prospective data. American journal of epidemiology. Nov 15 
2005; 162(1 0):983-990. 
Bellver J, Rossal LP, Bosch E, et al. Obesity and the risk of spontaneous abortion after 
oocyte donation. Fertility and sterility. May 2003; 79( 5): 113 6-1140. 
Blackmore KM, Wong J, Knight JA. A cross-sectional study of different patterns of oral 
contraceptive use among premenopausal women and circulating IGF-1: 
implications for disease risk. BMC women's health. 2011; 11: 15. 
Blohm F, Friden B, Milsom I. A prospective longitudinal population-based study of 
clinical miscarriage in an urban Swedish population. BJOG: an international 
journal of obstetrics and gynaecology. Jan 2008;115(2):176-182; discussion 183. 
Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous 
conception: a systematic review. Seminars in reproductive medicine. Nov 
2011;29(6):507-513. 
Bracken MB, Triche E, Grosso L, Hellenbrand K, Belanger K, Leaderer BP. 
Heterogeneity in assessing self-reports of caffeine exposure: implications for 
studies ofhealth effects. Epidemiology. Mar 2002;13(2):165-171. 
Brazier JL, Ritter J, Berland M, Khenfer D, Faucon G. Pharmacokinetics of caffeine 
during and after pregnancy. Developmental pharmacology and therapeutics. 
1983;6(5):315-322. 
BrownS. Miscarriage and its associations. Seminars in reproductive medicine. Sep 
2008;26(5):391-400. 
Buss L, Tolstrup J, Munk C, et al. Spontaneous abortion: a prospective cohort study of 
younger women from the general population in Denmark. Validation, occurrence 
113 
and risk determinants. Acta obstetricia et gynecologica Scandinavica. 
2006;85( 4):467-475. 
Caffeine content of food & drugs. www.cspinet.org/new/cafchart.htm Accessed May 13, 
2012. 
Cnattingius S, Signorello LB, Anneren G, et al. Caffeine intake and the risk offrrst-
trimester spontaneous abortion. New England journal of medicine. Dec 21 
2000;343(25): 1839-1845. 
Daugaard HO, Thomsen AC, Henriques U, Ostergaard A. Group B streptococci in the 
lower urogenital tract and late abortions. American journal of obstetrics and 
gynecology. Jan 1988;158(1):28-31. 
Davey Smith G, Hart C, Upton M, et al. Height and risk of death among men and 
women: aetiological implications of associations with cardiorespiratory disease 
and cancer mortality. Journal of epidemiology and community health. Feb 
2000;54(2):97-103. 
Dlugosz L, Belanger K, Hellenbrand K, Holford TR, Leaderer B, Bracken MB. Maternal 
caffeine consumption and spontaneous abortion: a prospective cohort study. 
Epidemiology. May 1996;7(3):250-255. 
Dlugosz L, Bracken MB. Reproductive effects of caffeine: a review and theoretical 
analysis. Epidemiologic reviews. 1992;14:83-100. 
Dominguez-Rajas V, de Juanes-Pardo JR, Astasio-Arbiza P, Ortega-Molina P, Gordillo-
Florencio E. Spontaneous abortion in a hospital population: are tobacco and 
coffee intake risk factors? European journal of epidemiology. Dec 1994; 
1 0( 6):665-668. 
Dorgan JF, Reichman ME, Judd JT, et al. The relation ofbody size to plasma levels of 
estrogens and androgens in premenopausal women (Maryland, United States). 
Cancer causes & control: CCC Jan 1995;6(1):3-8. 
Due P, Heitmann BL, Sorensen Tl. Prevalence of obesity in Denmark. Obesity reviews: 
an official journal of the International Association for the Study of Obesity. May 
2007;8(3): 187-189. 
Durrleman S, Simon R. Flexible regression models with cubic splines. Statistics in 
medicine. May 1989;8(5):551-561. 
Erickson JD. Down syndrome, paternal age, maternal age and birth order. Annals of 
human genetics. Jan 1978;41(3):289-298. 
114 
Fenster L, Eskenazi B, Windham GC, Swan SH. Caffeine consumption during pregnancy 
and spontaneous abortion. Epidemiology. May 1991;2(3):168-174. 
Fenster L, Hubbard AE, Swan SH, et al. Caffeinated beverages, decaffeinated coffee, and 
spontaneous abortion. Epidemiology. Sep 1997;8(5):515-523. 
Ferruzzi MG. The influence of beverage composition on delivery of phenolic compounds 
from coffee and tea. Physiology & behavior. Apr 26 2010;100(1):33-41. 
Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among 
US adults, 1999-2008. JAMA: the journal of the American Medical Association. 
Jan 20 2010;303(3):235-241. 
Ford JH, MacCormac L. Pregnancy and lifestyle study: the long-term use of the 
contraceptive pill and the risk of age-related miscarriage. Human reproduction. 
Jun 1995;10(6):1397-1402. 
Frederiksen P, Jensen KE, Kjaer SK. Sociodemographic factors and risk-taking 
behaviour during adolescence and obesity among more than 40 000 Danes. Public 
health nutrition. Oct 17 2012:1-8. 
Garcia-Enguidanos A, Martinez D, Calle ME, LunaS, Valero de Bernabe J, Dominguez-
Rajas V. Long-term use of oral contraceptives increases the risk of miscarriage. 
Fertility and sterility. Jun 2005;83(6):1864-1866. 
Garrido-Latorre F, Lazcano-Ponce EC, Lopez-Carrillo L, Hernandez-Avila M. Age of 
natural menopause among women in Mexico City. International journal of 
gynaecology and obstetrics. May 1996;53(2):159-166. 
Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and 
risk of colorectal adenoma in women (United States). Cancer causes & control: 
CCC. Mar 1996;7(2):253-263. 
Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural 
menopause in a multiethnic sample of midlife women. American journal of 
epidemiology. May 1 2001;153(9):865-874. 
Gold EB, Crawford SL, Avis NE, et al. Factors related to age at natural menopause: 
longitudinal analyses from SWAN. American journal of epidemiology. Jull 
2013; 178(1):70-83. 
Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Height and cancer 
incidence in the Million Women Study: prospective cohort, and meta-analysis of 
prospective studies of height and total cancer risk. The lancet oncology. Aug 
2011;12(8):785-794. 
115 
Greenwood DC, Alwan N, Boylan S, et al. Caffeine intake during pregnancy, late 
miscarriage and stillbirth. European journal of epidemiology. Apr 
2010;25( 4):275-280. 
Grosso LM, Bracken MB. Caffeine metabolism, genetics, and perinatal outcomes: a 
review of exposure assessment considerations during pregnancy. Annals of 
epidemiology. Jul2005;15(6):460-466. 
Harlap S, Shiono PH, Ramcharan S. Spontaneous foetal losses in women using different 
contraceptives around the time of conception. International journal of 
epidemiology. Mar 1980;9(1):49-56. 
Hatch EE, Wise LA, Mikkelsen EM, et al. Caffeinated beverage and soda consumption 
and time to pregnancy. Epidemiology. May 2012;23(3):393-401. 
Helgstrand S, Andersen AM. Maternal underweight and the risk of spontaneous abortion. 
Acta obstetricia et gynecologica Scandinavica. Dec 2005;84(12): 1197-1201. 
Higdon JV, Frei B. Coffee and health: a review of recent human research. Critical 
reviews in food science and nutrition. 2006;46(2): 101-123. 
Howards PP, Hertz-Picciotto I, Poole C. Conditions for bias from differential left 
truncation. American journal of epidemiology. Feb 15 2007;165(4):444-452. 
Huybrechts KF, Mikkelsen EM, Christensen T, et al. A successful implementation of e-
epidemiology: the Danish pregnancy planning study 'Snart-Gravid'. European 
journal of epidemiology. May 2010;25(5):297-304. 
Infante-Rivard C, Fernandez A, Gauthier R, David M, Rivard GE. Fetal loss associated 
with caffeine intake before and during pregnancy. JAMA: the journal of the 
American Medical Association. Dec 22-29 1993;270(24):2940-2943. 
Jacobs DR, Jr., Ainsworth BE, Hartman TJ, Leon AS. A simultaneous evaluation of 10 
commonly used physical activity questionnaires. Medicine and science in sports 
and exercise. Jan 1993;25(1):81-91. 
James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obesity 
research. Nov 2001;9 Suppl4:228S-233S. 
Jellesen R, Strandberg-Larsen K, Jorgensen T, Olsen J, Thulstrup AM, Andersen AM. 
Maternal use of oral contraceptives and risk of fetal death. Paediatric and 
perinatal epidemiology. Jul2008;22( 4):334-340. 
Kallen B, Finnstrom 0, Nygren KG, Olausson PO. Maternal and fetal factors which 
affect fetometry: use of in vitro fertilization and birth register data. European · 
116 
journal of obstetrics, gynecology, and reproductive biology. Aug 5 20 13. 
Khaw KT. Epidemiology of the menopause. British medical bulletin. Apr 
1992;48(2):249-261. 
Kirkinen P, Jouppila P, Koivula A, Vuori J, Puukka M. The effect of caffeine on 
placental and fetal blood flow in human pregnancy. American journal of 
obstetrics and gynecology. Dec 15 1983;147(8):939-942. 
Klein J, Stein Z. Epidemiology of chromosomal anomalies in spontaneous abortion: 
prevalence, manifestation and determinants. In: Bennett MJ, Edmonds DK, eds. 
Spontaneous and recurrent abortion. Oxford, UK: Blackwell Scientific 
Publications; 1987:p. 29. 
Kotsopoulos J, Eliassen AH, Missmer SA, Hankinson SE, Tworoger SS. Relationship 
between caffeine intake and plasma sex hormone concentrations in 
premenopausal and postmenopausal women. Cancer. Jun 15 2009;115(12):2765-
2774. 
Kristensen J, Langhoff-Roos J, Skovgaard LT, Kristensen FB. Validation of the Danish 
Birth Registration. Journal of clinical epidemiology. Aug 1996;49(8):893-897. 
Kroon B, Harrison K, Martin N, Wong B, Yazdani A. Miscarriage karyotype and its 
relationship with maternal body mass index, age, and mode of conception. 
Fertility and sterility. Apr 2011;95(5):1827-1829. 
Laara E, Rantakallio P. Body size and mortality in women: a 29 year follow up of 12,000 
pregnant women in northern Finland. Journal of epidemiology and community 
health. Aug 1996;50(4):408-414. 
Landres IV, Milki AA, Lathi RB. Karyotype of miscarriages in relation to maternal 
weight. Human reproduction. May 2010;25(5):1123-1126. 
Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first 
trimester and recurrent miscarriage: matched case-control study. Human 
reproduction. Jul 2004; 19(7): 1644-1646. 
Lawson CC, LeMasters GK, Levin LS, Liu JH. Pregnancy hormone metabolite patterns, 
pregnancy symptoms, and coffee consumption. American journal of 
epidemiology. Sep 1 2002;156(5):428-437. 
Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need 
for weight management. BMJ: British medica/journal. Jul15 
1995;311(6998): 158-161. 
117 
Li H, Nakajima ST, Chen J, Todd HE, Overstreet JW, Lasley BL. Differences in 
hormonal characteristics of conceptive versus nonconceptive menstrual cycles. 
Fertility and sterility. Mar 2001;75(3):549-553. 
Li HW, Wong CY, Yeung WS, Ho PC, Ng EH. Serum anti-mullerian hormone level is 
not altered in women using hormonal contraceptives. Contraception. Jun 
2011 ;83(6):582-585. 
Lohse SR, Farkas DK, Lohse N, et al. Validation of spontaneous abortion diagnoses in 
the Danish National Registry ofPatients. Clinical epidemiology. 2010;2:247-250. 
Lucero J, Harlow BL, Barbieri RL, Sluss P, Cramer DW. Early follicular phase hormone 
levels in relation to patterns of alcohol, tobacco, and coffee use. Fertility and 
sterility. Oct 2001;76(4):723-729. 
Maconochie N, Doyle P, PriorS, Simmons R. Risk factors for frrst trimester miscarriage-
-results from aUK-population-based case-control study. BJOG: an international 
journal of obstetrics and gynaecology. Feb 2007; 114(2): 170-186. 
Matijasevich A, Barros FC, Santos IS, Y emini A. Maternal caffeine consumption and 
fetal death: a case-control study in Uruguay. Paediatric and perinatal 
epidemiology. Mar 2006;20(2):100-109. 
Metwally M, Cutting R, Tipton A, Skull J, Ledger WL, Li TC. Effect of increased body 
mass index on oocyte and embryo quality in IVF patients. Reproductive 
biomedicine online. Nov 2007;15(5):532-538. 
Metwally M, Ong KJ, Ledger WL, Li TC. Does high body mass index increase the risk of 
miscarriage after spontaneous and assisted conception? A meta-analysis of the 
evidence. Fertility and sterility. Sep 2008;90(3):714-726. 
Metwally M, Saravelos SH, Ledger WL, Li TC. Body mass index and risk of miscarriage 
in women with recurrent miscarriage. Fertility and sterility. Jun 2010;94(1):290-
295. 
Mikkelsen EM, Hatch EE, Wise LA, Rothman KJ, Riis A, Sorensen HT. Cohort profile: 
the Danish Web-based Pregnancy Planning Study--'Snart-Gravid'. International 
journal of epidemiology. Aug 2009;38(4):938-943. 
Mikkelsen EM, Riis AH, Wise LA, Hatch EE, Rothman KJ, Sorensen HT. Pre-gravid 
oral contraceptive use and time to pregnancy: a Danish prospective cohort study. 
Human reproduction. May 2013;28(5):1398-1405. 
Mills JL, Holmes LB, Aarons JH, et al. Moderate caffeine use and the risk of 
spontaneous abortion and intrauterine growth retardation. JAMA: the journal of 
118 
the American Medical Association. Feb 3 1993;269(5):593-597. 
Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital and 
health statistics. Series 23, Datafrom the National Survey of Family Growth. Aug 
2010(29):1-44. 
Nassaralla CL, Stanford JB, Daly KD, Schneider M, Schliep KC, Fehring RJ. 
Characteristics of the menstrual cycle after discontinuation of oral contraceptives. 
Journal ofwomens health. Feb 2011;20(2):169-177. 
Nohr EA, Bech BH, Davies MJ, Frydenberg M, Henriksen TB, Olsen J. Prepregnancy 
obesity and fetal death: a study within the Danish National Birth Cohort. 
Obstetrics and gynecology. Aug 2005;106(2):250-259. 
Norell SE, Boethius G, Persson I. Oral contraceptive use: interview data versus pharmacy 
records. International journal of epidemiology. Dec 1998;27(6):1033-1037. 
Nuovo GJ, Cooper LD, Bartholomew D. Histologic, infectious, and molecular correlates 
of idiopathic spontaneous abortion and perinatal mortality. Diagnostic molecular 
pathology: the American journal of surgical pathology, part B. Sep 
2005; 14(3): 152-158. 
Palmer JR, Rosenberg L, Wise LA, Horton NJ, Adams-Campbell LL. Onset of natural 
menopause in African American women. American journal of public health. Feb 
2003;93(2):299-306. 
Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive 
disorders in women. Human reproduction update. Jul-Aug 2003;9(4):359-372. 
Pineles BL, ParkE, Samet JM. Systematic Review and Meta-Analysis of Miscarriage and 
Maternal Exposure to Tobacco Smoke During Pregnancy. American journal of 
epidemiology. Feb 10 2014. 
Pollack AZ, Buck Louis GM, Sundaram R, Lum KJ. Caffeine consumption and 
miscarriage: a prospective cohort study. Fertility and sterility. Jan 
201 0;93(1):304-306. 
Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal 
diameter: best simple anthropometric indexes of abdominal visceral adipose tissue 
accumulation and related cardiovascular risk in men and women. American 
journal of cardiology. Mar 1 1994;73(7):460-468. 
Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of self-
reported waist and hip circumferences in men and women. Epidemiology. Nov 
1990; 1 ( 6):466-4 73 . 
119 
Risch HA, Weiss NS, Clarke EA, Miller AB. Risk factors for spontaneous abortion and 
its recurrence. American journal of epidemiology. Aug 1988;128(2):420-430. 
Robker RL, Akison LK, Bennett BD, et al. Obese women exhibit differences in ovarian 
metabolites, hormones, and gene expression compared with moderate-weight 
women. The Journal of clinical endocrinology and metabolism. May 
2009;94(5): 1533-1540. 
Rothman KJ. Fetal loss, twinning and birth weight after oral-contraceptive use. New 
Englandjournal of medicine. Sep 1 1977;297(9):468-471. 
Rothman KJ, Greenland S, Lash TL Modern epidemiology. 3rd ed. Philadelphia: Wolters 
Kluwer Health/Lippincott Williams & Wilkins; 2008. 
Rothman KJ, Mikkelsen EM, Riis A, Sorensen HT, Wise LA, Hatch EE. Randomized 
trial of questionnaire length. Epidemiology. Jan 2009;20(1): 154. 
Sackoff J, Kline J, Susser M. Previous use of oral contraceptives and spontaneous 
abortion. Epidemiology. Jul1994;5(4):422-428. 
Savitz DA, Chan RL, Herring AH, Howards PP, Hartmann KE. Caffeine and miscarriage 
risk. Epidemiology. ian 2008;19(1):55-62. 
Savitz DA, Hertz-Picciotto I, Poole C, Olshan AF. Epidemiologic measures of the course 
and outcome of pregnancy. Epidemiologic reviews. 2002;24(2):91-1 01. 
Schliep KC, Schisterman EF, Mumford SL, et al. Validation of Different Instruments for 
Caffeine Measurement Among Premenopausal Women in the BioCycle Study. 
American journal of epidemiology. Apr 1 2013;177(7):690-'699. 
Schliep KC, Schisterman EF, Mumford SL, et al. Caffeinated beverage intake and 
reproductive hormones among premenopausal women in the BioCycle Study. 
American journal of clinical nutrition. Feb 2012;95(2):488-497. 
Semins MJ, Shore AD, Makary MA, Weiner J, Matlaga BR. The impact of obesity on 
urinary tract infection risk. Urology. Feb 2012;79(2):266-269. 
Signorello LB, McLaughlin JK. Maternal caffeine consumption and spontaneous 
abortion: a review of the epidemiologic evidence. Epidemiology. Mar 
2004; 15(2):229-239. 
Simic M, Wahlin IA, Marsal K, Kallen K. Maternal obesity is a potential source of error 
in mid-trimester ultrasound estimation of gestational age. Ultrasound in obstetrics 
& gynecology. Jan 2010;35(1):48-53. 
Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study 
120 
across five European countries. European journal of contraception & 
reproductive health. Jun 2004;9(2):57-68. 
Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors influencing the 
age at natural menopause. Journal of chronic diseases. 1987;40(11 ):995-1 002. 
Stein Z, Susser M. Miscarriage, caffeine, and the epiphenomena of pregnancy: the causal 
model. Epidemiology. May 1991;2(3):163-167. 
Streuli I, Fraisse T, Pillet C, Ibecheole V, BischofP, de Ziegler D. Serum antimullerian 
hormone levels remain stable throughout the menstrual cycle and after oral or 
vaginal administration of synthetic sex steroids. Fertility and sterility. Aug 
2008;90(2):395-400. 
Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A. Body mass index, waist girth, 
and waist-to-hip ratio as indexes of total and regional adiposity in women: 
evaluation using receiver operating characteristic curves. American journal of 
clinical nutrition. Jan 1998;67(1):44-49. 
Themeau TM, Grambsch PM. Modeling survival data: extending the Cox Model: 
Springer; 2000. 
Thoma ME, Hediger ML, Sundaram R, et al. Comparing apples and pears: women's 
perceptions of their body size and shape. Journal of womens health. Oct 
2012;21(10): 1074-1081 . 
Tolstrup JS, Kjaer SK, Munk C, et al. Does caffeine and alcohol intake before pregnancy 
predict the occurrence of spontaneous abortion? Human reproduction. Dec 
2003; 18(12):2704-271 0. 
Tworoger SS, Eliassen AH, Missmer SA, et al. Birthweight and body size throughout life 
in relation to sex hormones and prolactin concentrations in premenopausal 
women. Cancer epidemiology, biomarkers & prevention: a publication of the 
American Association for Cancer Research, cosponsored by the American Society 
of Preventive Oncology. Dec 2006;15(12):2494-2501. 
United States. Congress. Office of Technology Assessment. Reproductive health hazards 
in the workplace. Washington, D.C.: Congress of the U.S. For sale by the Supt. of 
Docs., U.S. G.P.O.; 1985. 
Valckx SD, DePauw I, De Neubourg D, et al. BMI-related metabolic composition of the 
follicular fluid of women undergoing assisted reproductive treatment and the 
consequences for oocyte and embryo quality. Human reproduction. Dec 
2012;27(12):3531-3539. 
121 
van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in 
epidemiology? Americanjournal of epidemiology. Dec 12010;172(11):1292-
1298. 
van Keep PA, Brand PC, Lehert P. Factors affecting the age at menopause. Journal of 
biosocial science. Supplement. 1979(6):37-55. 
Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ. Circulating levels of sex 
hormones and their relation to risk factors for breast cancer: a cross-sectional 
study in 1092 pre- and postmenopausal women (United Kingdom). Cancer causes 
& control: CCC. Jan 2001;12(1):47-59. 
Vessey M, Meisler L, Flavel R, Yeates D. Outcome of pregnancy in women using 
different methods of contraception. British journal of obstetrics and gynaecology. 
Jul 1979;86(7):548-556. 
Weathersbee PS, Lodge JR. Caffeine: its direct and indirect influence on reproduction. 
Journal of reproductive medicine. Aug 1977;19(2):55-63. 
Weinberg CR, Hertz-Picciotto I, Baird DD, Wilcox AJ. Efficiency and bias in studies of 
early pregnancy loss. Epidemiology. Jan 1992;3(1): 17-22. 
Wen W, Shu XO, Jacobs DR, Jr., Brown JE. The associations of maternal caffeine 
consumption and nausea with spontaneous abortion. Epidemiology. Jan 
2001; 12(1):38-42. 
Weng X, Odouli R, Li DK. Maternal caffeine consumption during pregnancy and the risk 
of miscarriage: a prospective cohort study. American journal of obstetrics and 
gynecology. Mar 2008;198(3):279 e271-278. 
Wiegratz I, Mittmann K, Dietrich H, Zimmermann T, Kuhl H. Fertility after 
discontinuation of treatment with an oral contraceptive containing 30 microg of 
ethinyl estradiol and 2 mg of dienogest. Fertility and sterility. Jun 
2006;85(6): 1812-1819. 
Wilcox AJ. Fertility and pregnancy : an epidemiologic perspective. Oxford; New York: 
Oxford University Press; 2010. 
Wilcox AJ, Weinberg CR, Baird DD. Risk factors for early pregnancy loss. 
Epidemiology. Sep 1990;1(5):382-385. 
Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. New 
Englandjournal ofmedicine. Jul28 1988;319(4):189-194. 
Willett W. Nutritional epidemiology. 2nd ed. New York: Oxford University Press; 1998. 
122 
Wilson NM, Laursen M, Lidegaard 0. Oral contraception in Denmark 1998-2010. Acta 
obstetricia et gynecologica Scandinavica. Ju12012;91(7):810-815. 
Wise LA, Mikkelsen EM, Rothman KJ, et al. A prospective cohort study of menstrual 
characteristics and time to pregnancy. American journal of epidemiology. Sep 15 
2011;174(6):701-709. 
Wise LA, Rothman KJ, Mikkelsen EM, Sorensen HT, Riis A, Hatch EE. An internet-
based prospective study of body size and time-to-pregnancy. Human 
rep roduction. Jan 2010;25(1):253-264. 
Yeung EH, Zhang C, Albert PS, et al. Adiposity and sex hormones across the menstrual 
cycle: the BioCycle Study.lnternationaljournal of obesity. Feb 2013;37(2):237-
243. 
Yeung EH, Zhang C, Hediger ML, Wactawski-Wende J, Schisterman EF. Racial 
differences in the association between sex hormone-binding globulin and 
adiposity in premenopausal women: the BioCycle study. Diabetes care. Oct 
201 0;33(1 0):2274-2276. 
Zhou XH, Eckert GJ, Tierney WM. Multiple imputation in public health research. 
Statistics in medicine. May 15-30 2001;20(9-10):1541-1549. 
Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and 
obesity-associated risk factors among whites in the third National Health and 
Nutrition Examination Survey: clinical action thresholds. American journal of 
clinical nutrition. Oct 2002;76(4):743-749. 
Ziomkiewicz A, Ellison PT, Lipson SF, Thune I, Jasienska G. Body fat, energy balance 
and estradiol levels: a study based on hormonal profiles from complete menstrual 
cycles. Human reproduction. Nov 2008;23(11):2555-2563. 
123 
CURRICULUM VITAE 
KRISTEN ANNE HAHN 
Boston University School ofPublic Health 
 
 
kahahn@bu.edu 
EDUCATION 
2014 Doctor of Philosophy 
2008 Masters of Public Health 
2006 Bachelor of Arts 
Epidemiology 
Boston University School of Public Health, 
Boston, Massachusetts 
Epidemiology 
University ofNorth Texas Health Science 
Center 
Fort Worth, Texas 
Biological Sciences 
Cornell University 
Ithaca, New York 
PROFESSIONAL EXPERIENCE 
201 0-present 
2009-2010 
2008-2010 
2006-2007 
2005 
Research Associate, Department of Epidemiology 
Boston University School of Public Health, Boston, MA 
Research Instructor, Department of Family Medicine 
University of North Texas Health Science Center, Fort Worth, TX 
Program/Project Coordinator, Department of Family Medicine, 
Primary Care Research Institute 
University ofNorth Texas Health Science Center, Fort Worth, TX 
Graduate Research Assistant, Department of Epidemiology 
University ofNorth Texas Health Science Center, Fort Worth, TX 
Laboratory Assistant, Department of Population Medicine 
Cornell University College of Veterinary Medicine, Ithaca, NY 
124 
TEACHING EXPERIENCE 
Fall2013 
Fall2013 
Spring 2013 
Fall2012 
Spring 2008 
Fall2007 
FELLOWSIDPS 
2010-2014 
2007-2008 
Cohort Studies- EP 875- Grader 
Boston University School of Public Health 
Advanced Epidemiology- EP 854- Grader 
Boston University School of Public Health 
Intermediate Epidemiology- EP 813- Head Teaching Assistant 
Boston University School of Public Health 
Advanced Epidemiology- EP 854- Teaching Assistant 
Boston University School of Public Health 
Intermediate Epidemiology- Teaching Assistant 
University ofNorth Texas Health Science Center 
Principles of Epidemiology- Teaching Assistant 
University ofNorth Texas Health Science Center 
Pre-doctoral Fellow, Boston University Reproductive, Pediatric 
and Perinatal Epidemiology Training Program (BURPPE) 
Boston University, Boston, MA 
Graduate Student Fellow, Minority K-12 Initiative for Teachers 
and Students (MKITS) 
University ofNorth Texas Health Science Center, Fort Worth, TX 
PEER-REVIEWED PUBLICATIONS 
Hahn KA, Wise LA, Riis AH, Mikkelsen EM, Rothman KJ, Banholzer K, Hatch EE. 
Correlates of menstrual cycle characteristics among nulliparous Danish women. Clinical 
Epidemiology 2013 Aug;5(1):311-9. 
Fulda KG, Johnson KL, Hahn K, Lykens K. Do unmet needs differ geographically for 
children with special health care needs? Matern Child Health J. 2012 Apr 26. 
125 
Fulda KG, Hahn KA, Young RA, Marshall JD, Moore BJ, Espinoza AM, Beltran NM, 
McFadden P, Crim AD, Cardarelli R. Recruiting Practie-based Rsearch Network 
(PBRN) physicians to be research participants: lessons learned from the North Texas 
(NorTex) needs assessment study. JAm Board Fam Med. 2011 Sep-Oct;24(5):610-5. 
Young RA, Fulda KG, Suzuki S, Hahn KA, Espinoza AM, Marshall JD, Moore BJ, 
Cardarelli R. The influence of research compensation options on Practice-based 
Research Network (PBRN) physician participation: a North Texas (NorTex) PBRN 
study. JAm Board Fam Med. 2011 Sep-Oct;24(5):562-8. 
PRESENTATIONS 
A prospective study of body mass index and risk of spontaneous abortion 
American Society for Reproductive Medicine- poster presentation 2013 
Prenatal exposure to CNS-acting drugs and childhood neurodevelopmental outcomes 
Society for Pediatric and Perinatal Epidemiologic Research Conference- poster 
presentation 2012 
Society for Epidemiologic Research Conference- poster presentation 2012 
Evaluation of bias due to loss to follow-up in an internet-based cohort study 
e-Epi Conference- poster presentation 2012 
Geographic variation of medical discrimination on cancer testing among African-
Americans and whites 
Center for Health Promotion and Disease Prevention Conference- poster presentation 
2009 
UNTHSC- Research Appreciation Day- poster presentation 2009 
AAFP Scientific Assembly- poster presentation 2009 
Panel Member: Recntitment challenges and ethical research 
NorTex Convocation of Practices Conference 2009 
Co-Presenter: Health Disparities Research at the Primary Care Research Institute 
Grand Rounds: Texas Center for Health Disparities 2009 
126 
Social predictors of adherence to anti-retroviral treatment among Dallas-Area African-
American women 
UNTHSC- Research Appreciation Day- poster presentation 2008 
Texas Conference on Health Disparities- poster presentation 2008 
American Public Health Association Conference- poster presentation 2008 
127 
